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ABSTRACT
Stimuli-responsive polymers have already showed tremendous promise in controlled and selfregulated drug delivery. Successful construction of responsive polymers requires amalgamation
of chemical, physical and biological principles. For careful therapy, a great deal of advantages
offered by stimuli-responsive polymers is essential. A small or modest change in the
environmental condition (e.g. temperature, pH, light) brings a sharp change in the properties of
the responsive polymers. „Smart‟ drug delivery systems utilize these principles to mimic the
biological response behavior to a certain extent. Synthetic polymers incorporated with stimuliresponsive behavior would be amenable to overcome some of the systemic and intracellular
delivery barriers. Development in material science has led to the engineering of variety of smart
polymers which respond to diverse biological stimuli.
The current research illustrates the development of two dual-stimuli-responsive polymers applied
for local drug delivery. The polymers form thermogels at body temperature and degrade in either
acidic or matrix metalloproteinase rich environments. The polymers were synthesized from
Pluronic® tri-block copolymers in two simple reaction schemes and thoroughly characterized for
structures, physicochemical properties and cytotoxicity. The underlying principles involved in
physicochemical behavior of polymers and polymer solutions were clearly discussed. The release
characteristics of different therapeutic agents such as small molecule drugs, genes and proteins
from the thermogels were investigated. Finally, to improve the release properties of small size
proteins, a nanocomposite thermogel system was developed. The nanocomposite thermogel was
ii

based on a nanoclay, laponite, and pH-sensitive thermogelling polymer. Finally, the
nanocomposite thermogel incorporated with laponite sustained the release properties of small
proteins comparing to regular thermogels. Taken all together, the novel thermosensitive
polymers and nanocomposite thermogel system have great potential for bioresponsive local drug
delivery where the amount of bioactive release entirely depends on physiological needs.
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CHAPTER-1
INTRODUCTION
As newer drug entities continue to be evolved, more efficient and intelligent ways of delivering
these drugs are also developed incessantly. For controlled and prolonged release of these drugs,
delivery systems made of smart polymers were generated. Unlike the conventional drug delivery
systems, the controlled delivery platforms are constructed to maintain the plasma drug
concentrations in desired therapeutic range and localize the drug to a particular body
compartment with a single dose. In order to apply the polymer therapeutic safely and confidently
for drug delivery or tissue engineering, it has to comply with an extensive list of criteria. Most
importantly, the polymer has to be water-soluble, non-toxic, non-immunogenic and
biodegradable. If the polymer is non-degradable, care should be taken to engineer an optimum
sized polymer which can be excreted safely to avoid accumulation in the body. If the polymer is
degradable, the safety of the degraded products needs to be evaluated.
Recently, many researchers started developing smart polymeric systems using stimuli-responsive
polymers. Different names such as stimuli-responsive polymers, intelligent polymers, smart
polymers, have been coined for synthetic polymers based on their chemical and physical
properties. The stimuli-responsive polymers offer myriad of advantages for drug delivery where
the responsive polymers become an active participant, rather than a passive vehicle, in the
optimization of therapy. The responsive polymers often adopt a more active role such as
releasing bioactives upon an external stimulus. The external stimulus results in an alteration of
1

polymer properties such as solubility, conformation, hydrophilic/lipophilic balance, degradation
and ability to release a bioactive molecule. A combination of several responses is also likely at
the same time. Therefore, the researchers are interested in constructing the polymer or polymeric
systems responsive to one or more stimuli available in the nature. The drug delivery systems
constructed using responsive polymers are divided into two major categories, viz. pulsed or
externally regulated and closed-loop or self-regulated or internally regulated systems. The
polymeric systems which respond to external stimuli such as temperature, pH, electric field,
magnetic field, light, microwave radiation, ultrasound, etc., are considered as pulsed or
externally regulated systems1-5. Similarly, the self-regulated systems will be controlled by the
stimuli generated inside the biological system such as pH, temperature, enzyme concentrations,
etc6-8. Although various responsive systems are reported in the literature, present discussion will
be limited to temperature, pH and enzymatic-responsive systems.
Temperature can be an external stimulus (i.e) generated artificially outside the body or an
internal stimulus originating inside the biological system. The present discussion emphasizes
mainly on in situ forming hydrogels based on temperature responsive polymers. These systems
are fluids at room temperature which can be introduced into the body in a minimally invasive
manner to gel at body temperature and also at desired location. These systems offer advantages
such as lack of risk based surgical procedure for implantation and ability to incorporate various
therapeutic agents by simple mixing. In addition, the systems show great flexibility in the
architecture by taking the shape of the body cavity or the defect when injected into the body.
Temperature responsive polymers have been gaining lot of attention as they don‟t use any
organic solvents or copolymerization agents for gelation. It is worth mentioning about two
important properties such as lower critical solution temperature (LCST) and upper critical
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solution temperature (UCST) of the polymers9. LCST and UCST are characterized by the
changes in the polymer solubility upon changing the temperature. The polymers, which become
insoluble upon heating, show LCST, whereas reverse phenomenon holds good for polymers with
UCST. The balance between hydrophilic and hydrophobic moieties in the polymer backbone,
usually, governs the changes during LCST or UCST. The phase separation at this temperature is
caused by the alteration of certain molecular interactions such as hydrogen bonds and
hydrophobic interactions. For example, at the LCST, polymer-polymer and water-water
interactions are more favorable comparing to the hydrogen bonding between polymer and water.
The dominated „like-like‟ interactions, lead to the dehydration of the macromolecule which,
finally, makes the molecular structure more hydrophobic. In case of amphiphilic polymers, the
polymer-polymer interactions are responsible for micelle packing and gel formation when
temperature is increased. Whatever may be the gelation mechanism, an ideal system should be a
free flowing fluid below body temperature and gel quickly when injected into the body. In
addition, these systems should not affect the healthy or unwanted tissue by changing the
environment (e.g. alteration of the pH of the surroundings) near the injection location. The
important classes of polymers that undergo sol-gel transition with temperature are poly(ethylene
glycol-b-propylene glycol-b-ethylene glycol) (PEG-PPG-PEG) copolymers and its analogs,
PEG/poly(D,L-lactide-co-glycolide) (PLGA) block copolymers and polypeptides/polypeptidebased copolymers10-12. Among the fore-mentioned classes, PEG-PPG-PEG copolymers
(Poloxamer or Pluronic®) have been studied extensively for the last few years13.
1.1. Review of PEG/PPG based temperature-sensitive polymers
Pluronic copolymers have surface active properties and have been used widely in pharmaceutical
research for the last 15 years. Pluronic® copolymers are non-ionic surfactants and consist of more
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than 30 different polymers. These are ABA-type triblock copolymers composed of PEO and PPO
blocks. Depending on the molecular weight and PEO to PPO block ratio, the polymers exist in
different physical states such as liquids, pastes and flakes or solids. Molecular weight and PEO
to PPO ratio of commercially available Pluronic® copolymers vary from 1100 to 14000 and 1:9
to 8:2 respectively. At an optimum concentration (critical gelation concentration) the polymer
solution forms thermoreversible gel. The unique in situ gel-forming behavior of Pluronic®
copolymers particularly suited for the delivery of bioactive agents viz. small molecule drugs,
proteins and genes. After administration into the body, Pluronic® gels can protract the drug
release compared to Pluronic® solutions. Most release profiles show that the release from
Pluronic® based thermogels is restricted to several hours and rarely exceeded a few days. This
particular property made Pluronic® thermogels attractive for short-term therapies such as
infection treatment, pain management and fertility control14-18. Apart from the parenteral route,
other administration routes were also evaluated. Nasal, ophthalmic, transdermal, vaginal and
rectal routes are the examples of other administration routes19-26. Rapid erosion of the gels
restricted the use of Pluronic® copolymers for long-term drug delivery. In addition to rapid
erosion, Pluronic® gels suffer from other drawbacks such as weak mechanical strength and nondegradability. Particularly, the non-degradability and weak renal elimination restrict the use of
high molecular weight Pluronic® copolymers in the drug delivery. To circumvent the problems,
new polymers have been synthesized by joining together several low molecular weight Pluronic®
units via biodegradable linkages10,27. Novel multiblock copolymers of Pluronic F127 have been
developed by coupling Pluronic® F127 monomers using hexamethylene diisocyanate or
phosgene as the coupling reagent28. The viscosities of the new polymer solutions were nearly 15
times higher than Pluronic® F127 at body temperature. The oligomerization not only improved
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the viscosities but also the release properties of the incorporated drug from the thermogel. The in
vitro release of a model drug (RG-13577) from the thermogel lasted for over 40 days, in contrast
to only seven days release from the thermogel at the same concentration. Ahn et al. developed a
series of biodegradable multiblock copolymers coupling Pluronic® P85 through terephthaloyl
chloride10. Depending on the molecular weight of the multiblock copolymers (4000-40000
g/mol), the gel duration lasted from several hours to several weeks. A class of new multiblock
copolymers based on PEG-PPG was synthesized by attaching PEG and PPG using carbonyl
chloride and diacyl chlorides as the coupling molecules29. The novel polymer solutions showed
markedly higher viscosities comparing with Pluronic® F127 solutions. Also, the alternating
ether-carbonate bonds within the multiblock copolymer structure made the copolymers
biodegradable. A series of pentablock copolymers was developed from grafting both ends of
Pluronic® F87 with Poly(D,L-lactic acid) (PLA) or Poly (ε-caprolactone) (PCL)30,31. In
comparison with Pluronic® F87, the pentablock copolymer showed lower critical micellization
temperature (CMT). Also, importantly, the pentablock copolymers retained the thermoresponsive
sol-gel transition behavior. A promising in vitro release of hydrophilic (procain hydrochloride)
and hydrophobic drug (9-(methylaminomethyl) anthracene) molecules was observed from PLA6F87-PLA6 and PCL4-F87-PCL4 thermogels, respectively. Cohn et al. synthesized degradable
Pluronic®-based poly(ether-ester-urethane) multiblock copolymers by coupling oligo(ester)Pluronic® F127-oligo(ester) pentablock copolymers using hexamethylene diisocyanate
(HMDI)32. By varying the polyester block length and the degree of the chain extension, the
rheological properties and degradation behavior of the copolymer hydrogels were regulated.
Recently, enzyme-mediated cross-linking micelles of Pluronic® F127 were proposed for drug
delivery and cell encapsulation33. Pluronic® F127 was end capped with tyramine to induce
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tyrosinase mediated cross-linking of Pluronic micelles. The enzyme mediated cross-linking
produced high-strength injectable hydrogels, also, exhibiting temperature-responsive sol to gel
behavior. The cross-linked gels showed enhanced mechanical strength comparing to unmodified
Pluronic gels under physiological conditions. In addition, interestingly, the crosslinked micelle
hydrogels released a macromer drug, fluorescein isothiocyanate–dextran (FITC-Dextran; 20
kDa), for 12 days which is significantly higher than the release from the thermogels prepared
from unmodified Pluronic® F127. Chung et al. used another approach to enhance the gel stability
and mechanical strength34. A series of multi-block Pluronic copolymers linked by Dlactide and L-lactide oligomers were synthesized and blended to form stereo complexed
hydrogels. The crosslinked hydrogels exhibited significantly lower critical gelation concentration
(CGC) and critical gelation temperature (CGT) values, compared to uncomplexed multi-block
copolymers. Finally, the stereocomplexed hydrogels were shown to release incorporated human
growth hormone for 13 days by a mixed diffusion/erosion mechanism. Liu et al. introduced a
thermosensitive hydrogel based on amphiphilic PCL-Pluronic-PCL block copolymers
synthesized via radical polymerization35. Surprisingly, the block copolymers produced gel to sol
transition as the temperature increased. The phenomenon was explained based on double layers
shell/core structure of PCL–Pluronic–PCL micelles. Also, hydrophobic interactions and partial
crystallization mechanisms were thought to play key role in the gelation.
1.2. Review of PEG/Polyester based temperature-sensitive polymers
Copolymers of PEG with hydrophobic aliphatic polyesters such as PLA, polyglycolide (PGA),
PCL and PLGA have shown thermosensitivity in aqueous solutions. Nearly 15 years ago, first
thermosensitive polymer of this class, PEG-poly(l-lactide)-PEG (PEG-PLLA-PEG), was
reported by Jeong and his co-workers6. Initially, a diblock copolymer, monomethoxy PEG
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(MPEG)-PLLA, was synthesized by ring-opening polymerization reaction between MPEG and llactide. Later, the diblock copolymer was coupled using HMDI to generate PEG-PLLA-PEG.
The triblock copolymer solution presented gel to sol transition upon increase in temperature and
the gel to sol transition was dependent on PLLA block length. A similar triblock copolymer,
PEG-PLA-PEG, was recently synthesized by replacing l-lactide with d,l-lactide (LA)36. Not
surprisingly, the polymer solutions showed temperature dependent gel-sol transition. Gelation at
low temperature was mainly due to hydrogen bonding between PEG blocks; whereas the high
temperatures resulted in hydrogen bond breakage and gel to sol transition. In addition to linearblock copolymers, star-block copolymer solutions were responsive to temperature.
Biodegradabale star-shaped PLLA-PEG block copolymers were the main examples under this
category37,38. Star-shaped polymers were the result of a coupling reaction between hydroxylterminated 3-armed poly(l-lactide) and α-monocarboxy- ω- monomethoxy poly(ethylene oxide).
Gelation of the polymer solutions was mainly attributed to micellar packing at low temperatures.
However, at high temperatures, dehydration and contraction of PEO chains destroyed the
micelle-packing and resulted in gel to sol transition. In addition, with increase in molecular
weight of PLLA block and PEO block, the critical gel concentration decreased, the boundary
curve shifted to the left, and the gel regions were expanded.
The concept of designing block copolymers that undergo gel to sol transition is interesting.
However, these systems have little clinical relevance, since the injections at elevated
temperatures with respect to body temperature is quite uncomfortable for patients. To overcome
the drawbacks associated with these systems, researchers introduced thermosensitive polymers
that undergo sol to gel transition at or near body temperature. PEG-PLGA-PEG (ABA-type)
triblock copolymers were developed for sol to gel transition at low temperatures11. In addition to
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sol to gel transition, the polymer solutions underwent gel to sol transition at elevated
temperatures. The gelation at low temperature was driven by micellar growth and close packing
of micelles and the second thermal transition (gel to sol transition) at high temperatures was
mainly due to breakage of micellear structure. The authors concluded that the gelation
temperature could be adjusted by varying PLGA and PEG block lengths and PLGA composition.
Another interesting triblock copolymer of this category was PLGA-PEG-PLGA (BABtype)12,39,40. Even though the architecture of the polymer was completely different from ABAtype polymers, BAB-type polymers showed thermosensitive gelation. Also, the synthesis of
BAB-type polymers was simpler comparing to ABA-type polymers, using HMDI as a coupling
agent. Since BAB-type polymer has two hydrophobic PLGA end blocks, the gelation mechanism
was different from ABA-type polymers. The BAB-type polymer formed micelles with
intermicellar bridges, whereas the ABA-type polymer self assembled into regular micelles with
hydrophobic core and hydrophilic shell, in aqueous solution. Below CGT, PLGA-PEG-PLGA
polymers formed some bridging micelles, however, due to low hydrophobicity of PLGA
segment, no gelation was noticed. With increasing temperatures to CGT, a bridged micelle
network was formed because of increased hydrophobicity of PLGA blocks, leading to sol to gel
transition. ReGel® (PLGA-PEG-PLGA: 1500-1000-1500) was developed by Zentner et al. for
long-term drug delivery applications12. At 23 wt%, the thermogels lasted for 6-8 weeks and ~4
weeks, in vitro and in vivo respectively. Later, the researchers found that the graft polymers of
PEG-g-PLGA and PLGA-g-PEG were superior to linear block copolymers (PEG-PLGA-PEG or
PLGA-PEG-PLGA) in controlling the time of persistence of gels41-43. PEG-g-PLGA copolymer
was synthesized by ring opening polymerization of LA and glycolide (GA) using a macro
initiator (hydroxy-pendent PEG), whereas PLGA-g-PEG copolymer was prepared by a one-step
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ring opening polymerization of LA, GA and epoxy-terminated PEG. The PEG-g-PLGA
copolymer showed sol to gel transitions above 16 wt% in water and the thermogels lasted for
only one week under physiological conditions. On the other hand, PLGA-g-PEG copolymers
also presented sol to gel transitions upon a temperature raise. Interestingly, the thermogels (29
wt%) of PLGA-g-PEG persisted for more than two months, a significant improvement
comparing to one week persistent time observed for the PEG-g-PLGA copolymer thermogel.
Authors investigated the gelation mechanism using 13C-nuclear magnetic resonance (13C-NMR)
spectroscopy, rheology, infrared spectroscopy and small-angle neutron scattering and concluded
that dehydration of PEG segments and micellar aggregation caused sol to gel transition 44. PEG
molecular weight and amount of PEG grafting were altered to obtain a gelation window suitable
for physiological conditions. In addition, the gel duration (one week to three months) was
completely optimized by mixing PEG-g-PLGA and PLGA-g-PEG in predetermined
propositions.
New group of block copolymers were studied by replacing hydrophobic moieties such as PLA,
PGA and PLGA with a crystalline hydrophobic polymer- PCL45-49. Similar to previous
polyesters, PCL was biocompatible and biodegradable. In addition, PCL copolymers offered a
powdery morphology, making them easier to handle than other polyesters. A diblock copolymer,
MPEG-PCL, was developed by activated ring opening polymerization between ε-caprolactone
and MPEG and the molecular weights of the final polymers were controlled with feed ratio of
reactants48. Aqueous solutions of MPEG-PCL exhibited gel to sol transition on temperature
increase. The authors injected MPEG-PCL (MW 2000-2300 Da) aqueous solutions (23 wt%) into
a rat and demonstrated the rapid gelation at body temperature. In vivo formed gels were
maintained for 1 month with minimum inflammation at the injection site. Subsequently, the same
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research group reported another set of MPEG-PCL copolymers with relatively low molecular
weight MPEG (MW 750 Da) and PCL (MW 1400-3000 Da)47. Interestingly, the diblock
copolymers were soluble in water at low temperatures and showed sol-to-gel-to-sol transition
upon continuous temperature increase. The data suggested that the molecular weight of MPEG
had a significant influence on the solubility of final polymer and the gelation pattern. Recently,
Jeong et al. introduced PEG-PCL-PEG and PCL-PEG-PCL triblock copolymers and the aqueous
solutions of the copolymers were soluble in water at low temperatures45,46. Further, the
copolymer solutions showed clear sol-to-gel-to-turbid sol transition on temperature increase. An
investigation into the gelation mechanism by dynamic light scattering and
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C NMR revealed

that the sol to gel transition was driven by micellar aggregation and the gel to sol transition
occurred due to breakage of core-shell structure. PCL-PEG-PCL was expected to be more
crystalline comparing to PCL-PEG-PCL because of high PCL content. Even though PCL-PEGPCL solution (20 wt%) was a clear transparent solution, it turned turbid in 1 hour at 20 °C
because of high crystallinity of the copolymer. More recently, poly(caprolactone-co-trimethylene
carbonate)-PEG-poly(caprolactone-co-trimethylene

carbonate)

(PCTC-PEG-PCTC)

was

introduced to overcome the problems associated with the crystallinity of PCL fragment49. The
triblock copolymer solution underwent sol to gel transition and produced very soft gel with a
storage modulus (G‟) of 1 Pa. Moreover, the gels lasted for 50 days at 37 °C in phosphate buffer.
The crystallinity of the final polymer was also dependent on the molecular weight of the PCL
segment. Multiblock copolymers, (PCL-PEG-PCL)n, were synthesized by joining several units of
PCL-PEG-PCL (1000-1000-1000) using terephthaloyl chloride50. Surprisingly, the multiblock
copolymer solution at 20 wt% did not turn turbid at room temperature indicating that increase in
molecular weight of the PCL fragment could decrease the crystallinity of final polymer.
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Moreover, multiblock copolymer solutions produced softer gels (G‟: 100 Pa) comparing to
triblock copolymer thermogels (G‟: 10000 Pa).
In addition to the molecular weight, stereoisomeric aspects of lactide group play an important
role in the physico-chemical properties of the final block copolymer51-55. To investigate this
effect, multiblock copolymers of PEG/poly(d,l-lactide) (PDLLA) and PEG/PLLA with similar
molecular weights were developed52. In comparison with PEG/PDLLA multiblock copolymer,
PEG/PLLA multiblock copolymer showed a lower critical gel concentration, a lower sol-to-gel
transition temperature, and a wider gel window. Also, at constant concentration, the maximal gel
modulus of the PEG/PLLA multiblock copolymer was significantly high comparing to
PEG/PDLLA multiblock copolymer. Extensive characterization revealed that that the differences
in the thermogel properties come from lower dynamic molecular motion and the higher
aggregation tendency of the PLLA due to the isotactic localization of the hydrophobic methyl
groups rather than crystallization of PLLA. Fujiwara et al. utilized the stereo-complexing ability
of enantiomeric triblock copolymers such as PLLA-PEG-PLLA and PDLA-PEG-PDLA, to
induce sol-gel transition51. Since the individual block copolymers did not show thermal gelation,
the main driving mechanism for sol to gel transition of the polymer mixtures was stereocomplexation. Another interesting criterion that influenced the thermal gelation was the end
group modification of thermosensitive copolymers56-59. Jo et al. aliphatically modified the
hydrophobic ends of poly(l-lactide-co-caprolactone)-b-PEG-b-poly(l-lactide-co-caprolactone)
(PLLACL-PEG-PLLACL) with hexanoyl and lauroyl groups for effective modulation of the
thermogelling properties56. Interestingly, the triblock copolymers acquired the thermogelling
property

after

aliphatic

modification.

The

results

suggested

that

the

hydrophilicity/hydrophobicity of a polymer could be adjusted by a careful terminal modification.
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Terminal group modifications using various other end caps (hydroxyl, acetyl, propionyl and
butanoyl groups) for PLGA-PEG-PLGA triblock copolymers have been reported58,59. In
summary, individual block length, molecular weight of the final polymer, polymer topology,
polymer concentration and end groups affected one or more of the polymer physical properties
such as aqueous solubility, gelation, gel modulus, kinetics of gelation and gel duration.
1.3. Review of polypeptide-based temperature-sensitive polymers
Research has been directed towards engineering novel thermosensitive materials with
biocompatible and biodegradable polypeptide backbones60-62. The ability of these materials to
self assemble into ordered structures (α-helix, β-sheet and random coil) makes them more
interesting. Polypeptides of triple-helix-forming collagen model peptide, (Pro-Hyp-Gly)10, and
thermosensitive elastin-derived pentapeptide, Val-Pro-Gly-Val-Gly, showed inverse phase
transition from transparent solution to turbid suspension upon increasing the temperature63.
Moreover, the polypeptides with more (82–86 mol %) Val-Pro-Gly-Val-Gly content showed
reversible gel formation, indicating that (Pro-Hyp-Gly)10 acts as a hydrated unit and Val-ProGly-Val-Gly acts as a thermosensitive crosslinking point. Triblock copolymers consisting of
elastin-like protein sequences (Val-Pro-Gly-Val-Gly repeats), hexahistidine metal-binding motifs
and hydrophobic end blocks, [(Ile-Pro-Ala-Val-Gly)4(Val-Pro-Ala-Val-Gly)]n, were developed
for heavy metal removal applications64. Even though the system was not designed for drug
delivery, the polymer solution (6 wt%) turned to a gel at 25 °C, suggesting potential applications
in drug delivery. Pochan et al. designed a de novo-peptide, MAX3, with thermosensitivity65. The
polypeptide in aqueous solution (2 wt%) turned from random coil to β-hairpin structure to
generate a strong gel network (G‟: 1100 Pa) at 75 °C. Another interesting diblock copolypeptide,
consisting of hydrophobic and charged blocks showed thermosensitivity60. The polypeptide
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solution turned to gel at elevated temperatures and the gelation was mainly due to ordered
packing of α-helical and β-strand segments and association of the hydrophobic domains. In
another study, physically crosslinked poly(amino acid) hydrogels were developed by a sol–gel
transition of amphiphilic poly(N-substituted α/β-asparagine)s in an aqueous solution66. Thermal
gelation was achieved by the introduction of alkyl groups into the backbone of poly(Nsubstituted α/β-asparagine)s to optimize the hydrophobicity of the polymer. Thermal gelation
was also evident in aqueous solutions of l/dl-polyalanine block copolymers67. Such polymers
were developed for successful chondrocyte three-dimensional culture. The population and
thickness of fibrous nanostructure of the hydrogel were dependent on the fraction of β-sheet
structure of polyalanine. In addition, the nanostructure of the hydrogel controlled the
proliferation and protein expression of encapsulated chondrocytes.
Novel thermosensitive polymers were developed by conjugating synthetic polymers such as
PEG, PEG-PPG-PEG, poly(2-hydroxypropyl methacrylamide), polystyrene, etc. with functional
polypeptides7,68-71. Conjugation of PEG with enzymatically degradable poly(alanine-co-phenyl
alanine) (PAF) resulted in thermosensitive PEG-PAF for biomedical applications7. Interestingly,
PEG-PAF showed thermal gelation at very low concentrations (3.0-7.0 wt%) in aqueous
solutions. Fourier transform infrared spectroscopy (FTIR),
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C-NMR and rheology data

suggested that the sol to gel transition was mainly due to PEG-PAF conformational change to βsheet from random coil. Jeong et al. modified the terminal groups of amphiphilic PEG-PPG-PEG
copolymers with polypeptides such as poly(Ala-co-Phe), Arg-Gly-Asp, poly(Ala-co-Leu) and
l/dl-poly(Ala)69,72-74. Thermosensitive Pluronic® F68 copolymer consisting of a hydrophobic
unit, oligo-LA/oligo-CL, and a cell-adhesive peptide, Arg-Gly-Asp, was investigated for drug
delivery and tissue engineering applications72. Modified Pluronic® F68 showed gel-to-sol-to-gel
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transition and the gelation properties were affected by chain length of oligo-LA/oligo-CL, and
the concentration of the polymer solutions. PEG-PPG-PEG triblock copolymers with different
molecular weights (600 and 900 Da) and PEG/PPG ratios (~2.4 and ~4.4) were end-capped with
l/dl poly(Ala) for variable gelation properties69. Structure-property relationship data suggested
that the sol to gel transition temperature of the polymer solutions decreased with increased PA
block length, decreased PEG-PPG-PEG length and increased l-Ala/dl-Ala ratio. Recently, the
same research group modified the end blocks of PEG-PPG-PEG triblock copolymers with
poly(Ala-co-Phe) and poly(Ala-co-Leu)73,74. Both polymers showed sol to gel transition in the
concentration and temperature range 3.0-10.0 wt% and 10-50 °C, respectively. Random coil to βsheet conformational change of the polymers was considered to be the gelation mechanism in the
aqueous solution. Thermogles of poly(Ala-co-Leu) end-capped polymers were specifically
degraded in presence of matrix metalloproteinase and elastase, showing high sensitivity towards
proteolytic enzymes.
1.4. Organization of the thesis
Chapter 2 discusses the synthesis of Pluronic® based multiblock copolymers prepared via pHsensitive acetal linkages. Also, the extensive characterization of polymers using several
physicochemical characterization techniques (NMR, gel permeation chromatography (GPC),
differential scanning calorimetry (DSC), circular dichroism (CD), etc.) has been provided in this
chapter. pH is an important indicator, which can be used as a stimulus for pH-responsive
polymers. The pH profile of different tissues and cellular compartments varies differently. Blood
(pH 7.35-7.45), stomach (pH 1.0-3.0), duodenum (pH 4.8-8.2), colon (pH 7.0-7.5), early
endosome (pH 6.0-6.5), late endosome (pH 5.0-6.0), lysosome (pH 4.5-5.0) and golgi (pH 6.4)
have different pH conditions. Not only the pH conditions of healthy tissues but also the pH of
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pathological tissues, such as upon acquisition of inflammation, infection and cancer (pH 6.5- 7.4)
vary prominently. Therefore, the changes in the pH conditions have been the basis for the
construction of current pH-responsive polymers. Figure 1 clearly shows the concept of thermogel
formation and drug release in low pH conditions.

Figure 1: Schematic representation showing thermogel formation at body temperature followed
by polymer degradation and drug release in acidic conditions.
Chapter 3 discusses drug release from pH-sensitive thermogels for different therapeutics agents.
In addition, extensive characterization for drug loaded polymer solutions has been reported.
Chapter 4 reports a nanocomposite thermogel (NCT) comprising pH-sensitive polymer and a
synthetic nanoclay (laponite) for sustained release of small proteins.
The discussion in Chapter 5 is based on Pluronic® multiblock copolymers synthesized via
matrix metalloproteinase (MMP)-sensitive peptide linkages. MMPs play a critical role in tumor
progression, angiogenesis and metastasis. Particularly, MMP 2 and 9 which degrade extracellular
matrices have been known to be overexpressed in many types of cancers.
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Figure 2: Schematic representation showing thermogel formation at body temperature and
bioresponsive drug release in response to MMP levels.
The current polymers were designed to respond to MMPs overexpressed in the cancers. Figure 2
portrays the concept of thermal gelation and MMP-dependent degradation of the polymer and
drug release.
Chapter 6 summarizes the entire research work.
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CHAPTER-2
pH-SENSITIVE THERMOGELLING POLYMER FOR DRUG DELIVERY
2.1. Abstract
A class of thermosensitive biodegradable multiblock copolymers (MBCPs) with acid-labile
acetal linkages were synthesized from Pluronic® triblock copolymers (Pluronic® P85 and P104)
and di-(ethylene glycol) divinyl ether. The novel polymers were engineered to form thermogels
at body temperature and degrade in acidic environment. The Pluronic®-based acid-labile
polymers were characterized using NMR, GPC and DSC. In vitro biocompatibility of the
synthesized polymers was evaluated using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium
bromide (MTT) assay. The polymers showed reverse thermogelling behavior in water around
body temperature. The sol-gel transition temperatures of the polymers synthesized from
Pluronic® P85 and P104 were lowered from 70.3 to 30 oC and from 68.5 to 26.9 oC, respectively,
when the synthesized polymers were compared with corresponding Pluronic® block copolymers
at a concentration of 25 wt%. The hydrophobic dye solubilization confirmed the formation of
polymeric micelles in the aqueous solution. The sizes of multiblock copolymer increased upon a
temperature rise indicating that thermal gelation was mediated by micellar aggregation. The
novel polymers hold great potential as a pH-sensitive controlled drug delivery system due to
their interesting phase transition behavior and biocompatibility.
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2.2. Introduction
Recent advances in smart polymeric materials have brought a great promise for the development
of bioresponsive drug delivery systems which are able to release therapeutic molecules in
response to the signals stemming from diseased tissues75,76. Especially, biodegradable polymers
which respond to temperature have been extensively considered as an effective injectable
biomaterial for the delivery of small molecule drugs, proteins and genes6,77-81. These polymers
are uniquely suited to minimally invasive therapeutic interventions by providing free flowing
liquids below body temperature which turn into in situ gels upon injection12,43.
More recently, dual-stimuli-sensitive polymers with thermosensitivity have been evolved76,82-84.
Poly(2-diethylaminoethyl-methyl

methacrylate)-PEG-PPG-PEG-poly(2-diethylaminoethyl-

methyl methacrylate), a pentablock copolymer which is pH-sensitive thermogelling polymer has
been synthesized from Pluronic® F127 triblock copolymers via controlled atom transfer radical
polymerization82. The pentablock copolymer exhibits pH-sensitive micellization and
thermoreversible sol-gel transitions in water. Poly(β-amino ester) has also been used as a duofunctional group in the synthesis of poly(β-amino ester)-PCL-PEG-PCL-poly(β-amino ester), a
thermosensitive pH-sensitive pentablock copolymer83. The pentablock copolymer was
synthesized by the coupling of pH-sensitive poly(β-amino ester) to thermosensitive
biodegradable PCL-PEG-PCL. An interesting dual-stimuli-sensitive polymer has been based on
acid-labile acetal linkages which have provided an effective mechanism of polymer
biodegradation in an acidic medium85. Polyacetal-based temperature/pH-sensitive polymers were
synthesized by grafting PEG to a polyacetal backbone84. The PEG-grafted polyacetal has formed
a thermogel which favorably erodes at an acidic pH. Another thermosensitive polymer with dual
sensitivity has been introduced by the incorporation of bioreducible disulfide bonds in the
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polymer backbone76. These dual sensitive polymers are advantageous over other thermosensitive
polymers in that the release of a pharmacologically active agent can be triggered by an acidic
milieu of a diseased tissue or intracellular compartments. The specific pH for the degradation of
acetal-based polymers can be found in extracellular tumor fluid (pH 6.5 - 7.2) and endosomes
(pH 5 – 6.5) which is lower than the pH of the normal tissues86-90.
Even though a variety of dual-stimuli-sensitive polymers have been reported, their syntheses
usually require complicated multi-step reactions82,83. In addition, the responses of the polymers
to each stimulus are usually slow because of the chemico-structural restrictions for the dual
sensitivity84,85. The purpose of this study is to synthesize novel Pluronic®-based multiblock
copolymers connected via acid-labile acetal bonds rendering facilitated pH-sensitive
biodegradation. The hypothesis behind this novel polymer is that the combination of
thermosensitive Pluronic® and acid-labile acetal linkages would result in a dual-sensitive
polymer which can form gel at body temperature and allow bioresponsive polymer degradation
at an acidic pH. In this body of work, we demonstrated the acid-catalyzed degradation of the
polymers.
2.3. Experimental
2.3.1. Materials
Pluronic® P 85 and P104 were kindly provided from BASF Chemical Company (Florham Park,
NJ). Polystyrene standards of molecular weights 1, 4, 20, 50 and 100K were obtained from
Polysciences, Inc. (Warrington, PA). p-Toluenesulfonic anhydride, anhydrous tetrahydrofuran
(THF), 1, 6-diphenyl-1, 3, 5-hexatriene (DPH) and anhydrous toluene were purchased from
Acros Organics (Morris Plains, NJ). Di-(ethylene glycol) divinyl ether (DEGDVE) was obtained
from Aldrich (Milwaukee, WI). FITC-Dextran of molecular weight 40kDa was purchased from
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Sigma (Saint Louis, MO). Petroleum ether and methylene chloride from Fisher (Pittsburgh, PA)
were of analytical grade and used as supplied.
2.3.2. Polymer synthesis
Fifteen grams of Pluronic® P85 (MW 4600) or P104 (MW 5900), and 0.03 molar equivalent of
p-toluene sulfonic anhydride to Pluronic® were dissolved in 150 mL of anhydrous toluene. The
mixture was dried by distilling off 100 mL of toluene. DEGDVE was added to the dry mixture at
a 1:1 molar ratio to Pluronic®. The reaction was carried out overnight by magnetic stirring at 50
o

C under dry nitrogen. Upon completion of the reaction, the reaction solution was mixed with

150 mL of petroleum ether to precipitate polymer. The polymer precipitate was dissolved in a
dilute sodium hydroxide solution at a 2:1 molar ratio of NaOH to p-TSA to achieve a
concentration of 15 wt% at 4 oC. The aqueous polymer solution was heated to 75oC to precipitate
the polymer. After dissolving the crude precipitated polymer in distilled water at a concentration
of 20 wt%, the polymer was precipitated again by heating. The polymer was purified by another
cycle of dissolving by cooling and precipitation by heating. The final precipitate was freeze-dried
to obtain white powder. Two different thermosensitive Pluronic®-based MBCPs, MBCP-1 from
Pluronic® P85 and MBCP-2 from Pluronic® P104, were finally obtained. The yields of the
reactions were 90% and 87%.
2.3.3. Polymer characterization
Chemical structures of the synthesized polymers were analyzed by 1H-NMR. Polymers were
dissolved in CDCl3 and recorded on a 400MHz NMR spectrometer (Bruker Ultrashield TM 400
PLUS, Germany). Molecular weights of the synthesized MBCPs and Pluronic® copolymers were
determined by GPC. GPC was run on a Waters system equipped with a binary pump (Waters
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1525), a refractive index detector (Waters 2414), and a Styragel HR4E column (300 × 7.8 mm
I.D., 5 µm particle size). Tetrahydrofuran (THF) as a mobile phase was eluted at a flow rate of
1.00 mL/min at 25 oC. Polystyrene standards in the molecular weight range of 4,000-100,000
Daltons were also run to obtain a calibration curve. Molecular weights of the synthesized
polymers were calculated from the obtained calibration curve. Melting temperatures of the
synthesized polymers were determined by DSC. Thermograms were obtained by running the
polymer samples sealed in aluminum pans on a Diamond DSC (Perkin Elmer, Waltham, MA) in
the temperature range of -30 to 100 oC with a heating and cooling rate of 5 oC/min. Initially the
samples were equillibriated at -30 oC for 15 min. Dry nitrogen was continuously supplied at a
flow rate of 20 mL/min during the analysis.
2.3.4. Critical micelle concentration (CMC) of MBCP
The CMCs of MBCPs were determined by a dye solubilization method with 1, 6-diphenyl-1, 3,
5-hexatriene (DPH) 10. DPH of 0.4 mM in methanol was used in this CMC determination. Stock
solutions of MBCP-1 and -2 were prepared at a concentration of 10 wt%. Polymer solutions in
the concentration range of 10.0 to 1.0 × 10-5 wt% were prepared by serial dilutions of the stock
solutions. Then, 25 µL of the DPH solution was added to 2.5 mL of each polymer solution. The
polymer solutions were incubated for 24 h in a dark place. The absorbencies of the test solutions
were recorded on a Lambda EZ201 UV spectrophotometer (Perkin Elmer, Waltham, MA) at
wavelengths 377 and 391nm.
2.3.5. Degradation of MBCP
The MBCP solutions were prepared at a concentration of 25 wt% in deionized water. The
polymer solution (100µL) was placed in 1mL vials and the vials were kept at 4 oC overnight.
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Later, the polymer solutions were incubated at 37 oC for 15 min for gelation. After gelation,
200µL of phosphate buffer (pH 5.0, 6.5 and 7.4) was added to the vials. After gel degradation for
a predetermined time, the gels were frozen and lyophilized for GPC measurements. The dried
polymer was dissolved in 1ml dichloromethane and centrifuged at 10000 rpm for 10 min to
remove the buffer components. The supernatants were collected and vacuum dried to prepare
GPC samples. GPC was run to determine the distribution of polymer molecular weight.
2.3.6. In vitro cytotoxicity of MBCP
Calorimetric MTT assay was used to test the cytotoxicity of MBCP-1 and MBCP-2 on NIH 3T3
mouse embryonic fibroblast cells which have been widely used for the evaluation of in vitro
biocompatibility of biomaterials91-93. Initially, NIH 3T3 cells were cultured in Dulbecco‟s
Modified Eagle‟s Medium (DMEM) supplemented with 10 % fetal bovine serum (FBS) and
antibiotics. The cultured cells were seeded in 96 well plates at a density of 5 × 103 cells/well in
0.2 ml of the cell culture medium and grown for 24 h at 37 oC. After removing the culture
medium, 100 µl of an MBCP solution of which concentration ranged from 0.1 to 5.0 % (w/v) in
DMEM supplemented with 10 % FBS were placed on the top of the cell layer. The cells were
incubated for an additional 48 h and the metabolic activity of the cells was measured. After
removal of the test solution, 100 µl of fresh culture medium containing 50 µg MTT was added to
each well and the cells were incubated for 4 h. Lysis buffer comprising of 10 % (w/v) sodium
dodecyl sulfate and 45 % (v/v) dimethyl formamide was then added and incubated for another 24
h. Absorbance was measured at 590 nm on a Model 550 microplate spectrophotometer (Bio-Rad,
Laboratories Inc., Hercules, CA). Cell viability was calculated as compared to phosphate
buffered saline (PBS)-treated cells (100 % survival).
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2.3.7. Dynamic light scattering (DLS)
The apparent particle sizes and particle size distributions of the MBCPs were measured using
DLS. A concentration (4% w/v) above CMC was chosen to study the micellar aggregation as a
function of temperature. Zetasizer Nano S (Malvern Instruments, Malvern, UK) was used to
measure the particle size of the samples. The instrument was operated at four different
temperatures such as 10, 20, 30 and 40 oC.
2.3.8. Thermal gelation of MBCP solutions
2.3.8.1. Test tube inverting method
A series of MBCP solutions at concentrations of 5, 10, 15, 20 and 25 wt% were prepared in
deionized water. One milliliter of each polymer solution was transferred to each 4mL vial and
the vials were kept at 4 oC overnight. The vials were then placed in a water bath and equilibrated
at 15 oC for 15 min. The sol-gel and gel-sol phase transitions of the polymer solutions were
tested by tube inversions in the temperature range of 15 to 80 oC while heating the polymer
solutions at a rate of 2 oC per every 5 min11,42,56,76. The temperature at which a polymer solution
stopped flowing upon a tube inversion was recorded as gelation temperature. Phase transitions of
the solutions of Pluronic® P85, Pluronic® P104, MBCP-1 and MBCP-2 were determined by the
method.
2.3.8.2. Falling ball method
The solutions of MBCP-1 and MBCP-2 were prepared at a concentration of 25 wt% in
deinonized water. One milliliter of each polymer solution was placed in a NMR tube with a
diameter of 4.0 mm. The time (t) required for a steel ball (diameter (D) =1.97 mm, density (ρs) =
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7.97 g/mL) to fall a specified distance (d = 3 cm) was measured with a temperature increment of
2 oC per step for each polymer concentration. The polymer solutions were equilibrated for 20
min at each temperature. A graph was plotted between temperature and the dynamic viscosity.
The velocity of the falling ball (v) can be calculated from the formula d/t. The density of the
polymer solution (ρf) was assumed to be 1.0 g/cm3. The specific gravities of the sphere (γs) and
the polymer solution (γf) were calculated using the formula γ = ρg (acceleration due to gravity
(g) = 980 cm/s2). Finally the dynamic viscosity (µ) was calculated using the following formula
µ = (γs - γf) D2/ (18v)
2.4. Results & Discussion
A facile approach to engineer a pH-sensitive thermogelling multiblock copolymer has been
demonstrated in this research work. Pluronic® (P85 and P104), a group of triblock copolymer of
PEG-PPG-PEG, has been used for the synthesis of acid-labile thermosensitive biodegradable
MBCPs. Figure 3 shows the synthetic reaction between Pluronic® copolymer and DEGDVE in
presence of p-toluenesulfonic anhydride as a catalyst, which results in MBCP with acetal
linkages. The reaction requires anhydrous conditions because a trace amount of water leads to a
premature termination of the oligomerization, which results in low molecular weight MBCP 85.
Water molecules are known to compete with hydroxyls to form hemiacetal intermediates. Hence,
the reactants were azeotropically dried to remove water adsorbed on Pluronic® prior to
oligomerization. Polyacetal formation between divinyl ether and hydroxy-terminated monomers
is favorable even at mild temperature94-96.
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Figure 3: Synthetic reaction scheme for the preparation of MBCPs from PEG-PPG-PEG
triblock copolymer (Pluronic®).
At around 40C, the polymerization is completed within 1 h. However, we have reacted
Pluronic® and DEGDVE overnight at 50C to ensure a successful oligomerization because
Pluronic® of molecular weight around 5000 may not be readily accessible for the
oligomerization. Thickening of the reaction mixture was observed in 4-5 h after the addition of
DEGDVE. Upon completion of the oligomerization, p-TSA was immediately neutralized by
dissolving the resulting polymer in a dilute sodium hydroxide solution in order to prevent
polymer degradation by acid-catalyzed hydrolysis during purification.
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Figure 4: Gel permeation chromatograms of (a) MBCP-1, (b) Pluronic® P85, (c) MBCP-2 and
(d) Pluronic® P104. The retention times of the synthesized polymers (~8.1) were different from
the Pluronic® copolymers (~9.2) indicating the formation of MBCPs.
MBCPs were precipitated by heating the solution to 70C. The polymers could be further
purified in a complete aqueous environment by the cycle of cooling and heating, which would be
advantageous for pharmaceutical applications of the polymers because harmful organic solvents
can be avoided during the purification process.
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Figure 5: Gel permeation chromatograms of MBCP-2 (a) after the synthesis, (b) after the
purification in aqueous NaOH and (c) after the purification in water.
In addition, unreacted Pluronic® and DEGDVE could be removed by the polymer purification
method. As shown in Figure 4, purified MBCPs include only trace amounts of the unreacted
Pluronic® copolymers. Moreover, GPC chromatographs in Figure 5 shows that the purification
process removed most of the remaining Pluronic®. Chromatograph of crude MBCP right after
synthesis indicates that the crude polymer contains a significant amount of unreacted Pluronic®
(Figure 5a). However, the purification of the crude polymer via repetitive precipitation in hot
water was able to remove most of free Pluronic® (Figure 5c).
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Figure 6: 1H-NMR spectrum of MBCP-1. A quartet (d) at 4.75 ppm from acetal groups and a
doublet (e) at 1.30 ppm from methyl protons of acetal groups indicated successful synthesis of
MBCPs.
Chemical structures of the synthesized MBCPs were confirmed by NMR spectroscopy. The 1HNMR spectra of Pluronic® P85 and P104 and their multiblock copolymers were obtained in
CDCl3. A typical 1H-NMR spectrum of MBCP is shown in Figure 6. This NMR spectrum of
MBCP-1 shows methyl protons of PPG (-CH2CH (CH3) O-) at 1.0-1.2 ppm, methylene and
methine protons of PPG (-CH2CH (CH3) O-) at 3.2-3.6 ppm, and methylene protons of PEG (CH2CH2O-) at 3.6 ppm. The acetal bond formation was confirmed by a quartet at 4.75 ppm
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assigned as methine protons of acetal groups and a doublet at 1.30 ppm from methyl protons of
acetal groups. The characteristic NMR peaks of acetal groups are consistent with previously
reported results85. In the case of divinyl linkers, hydrophobic linkers such as butanediol divinyl
ether and cyclohexane dimethanol divinyl ether would replace hydrophilic DEGDVE. However,
the incorporation of hydrophobic linkers between hydrophilic PEG blocks of Pluronic ® would
result in different gelation behavior from the MBCP synthesized with DEGDVE.
The synthetic method demonstrated in this work is simple compared to previous syntheses for
pH-sensitive thermogelling polymers. Previous synthesis of pH-sensitive thermogelling polymer
involved multi-step reactions that included polyacetal synthesis and following PEG grafting84.
Gel permeation chromatography was used to determine the number-average molecular weight
(Mn) and polydispersity index of Pluronic® copolymers and MBCPs. These values are
summarized in Table 1. The calculated molecular weights of MBCP-1 and MBCP-2 were 36920
(±1650) and 40210 (±860) g/mol, respectively. The GPC measurements also indicate that the
synthesized polymers are multiblock copolymers with 4.9 and 4.1 Pluronic® units in MBCP-1
and MBCP-2 respectively.
The reasons for the relatively low molecular weight oligomers may be the presence of trace
water even after azeotropic distillation and limited availability of end hydroxyl groups of large
Pluronic® molecules for the oligomerization. Based on DSC analysis, melting temperatures (Tm)
of Pluronic® have been changed after the oligomerization in the presence of DEGDVE. Tm
values of MBCP-1 and MBCP-2 were 29.0 oC and 29.8 oC respectively while Pluronic® P85 and
P104 have Tm values of 38.9 oC and 39.4 oC respectively.
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Table 1: Characterization results of the synthesized MBCPs.

Polymer

Mn (g/mol) a

Mw/Mn b

Number of
repeating units

Tm ( oC)c

Pluronic® P85

7500 (4600d)

1.04

-

38.9

Pluronic® P104

9800 (5900e)

1.04

-

39.4

MBCP 1

37000

1.8

4.9

29.0

MBCP 2

40000

1.77

4.1

29.8

a

Number average molecular weights determined by GPC

b

Polydispersities based on GPC measurements

c

Melting temperatures determined by DSC

d,e

Molecular weights from BASF chemical company

The changes in Tm might be the result of interrupted polymer packing by the addition of acetal
bonds between PEG blocks of Pluronic®. CMCs of MBCP-1 and MBCP-2 were determined by a
hydrophobic dye solubilization method which has been frequently employed for the
characterization of amphiphilic block copolymers10. DPH, a hydrophobic dye used in this study,
has a tendency to partition into the hydrophobic core of the micelles in the presence of
amphiphilic block copolymers. The solubility and UV absorbance of DPH sharply increase at the
CMCs of the amphiphilic polymers. The CMCs of amphiphilic block copolymers can be
calculated by extrapolating the absorbance versus logarithmic concentration (Figure 7).
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Figure 7: Determination of CMC of the synthesized MBCPs by the dye solubilization. The
difference in the absorbance of DPH at 377 and 391nm was plotted on vertical axis. The crosssection point of the two exponential lines was defined as the CMC. The CMCs of MBCP-1 and
MBCP-2 were 2.854 (± 0.030) wt% and 0.485 (± 0.009) wt%, respectively.
The CMCs of MBCP-1 and MBCP-2 were found to be 2.854 (±0.030) wt% and 0.485 (±0.009)
wt%, respectively. The CMC difference between MBCP-1 and MBCP-2 is due to the difference
in the ratio between hydrophobic PPG and hydrophilic PEG. MBCP-2 was expected to have a
lower CMC than MBCP-1 because Pluronic® P104 has a greater PPG/PEG ratio than Pluronic®
P85. In the case of amphiphilic block copolymers based on PEG and PPG, a block copolymer
with a greater PPG/PEG ratio generally has a lower CMC 97.
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Figure 8: In vitro cytotoxicity of the synthesized MBCPs as a function of copolymer
concentration. Cell viability was determined by an MTT assay using cultured NIH 3T3 mouse
embryonic fibroblast cells. The results represent the means  SD for n=3.
Cytotoxicity of the synthesized MBCPs has been evaluated by an MTT assay using NIH 3T3
mouse embryonic fibroblast cells. The MTT assay was performed in the concentration range 0.1
to 5.0% (w/v) and these results are shown in Figure 8. It was difficult to perform the assay
above 2.5% (w/v) polymer concentration because of pronounced polymer aggregate formation at
37 oC. During the experiment, the removal of polymer aggregates via pipetting resulted in a
slight suction of testing cells, which might cause an underestimation of cell viability. Even with
the presumed underestimation of cell viability, MBCP solutions showed overall cell viability
greater than 80%. In addition, thermal gelation of MBCP is not expected to leave a significant
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amount of the polymer as unimers or micelles only which can penetrate cell membrane and thus
affect cell viability. Taken together, the synthesized MBCPs are not considered as cytotoxic and,
as such, hold great potential for biomedical and pharmaceutical applications. It is vital that
polymer degradation products should also be non-toxic. Degradation of acetal bond yields an
equal amount of acetaldehyde85. Due to very low amount of degraded products compared to the
initial polymer, the cytotoxicity associated with the degraded products, is expected to be
minimal. Phase transitions of aqueous solutions of Pluronic® copolymers and MBCPs were
evaluated by a test tube inverting method. The sol-gel transitions of the polymeric solutions were
determined by flow (sol) – no flow (gel) basis. Aqueous solutions of both MBCPs underwent
sol-gel and gel-sol phase transitions upon temperature increments. As shown in Figure 9, the
temperatures at which the phase transitions occurred were dependent on polymer concentration.
Aqueous solutions of MBCPs were transparent at room temperature and turned into gels within
two minutes as the temperature reached 30-37 oC. These MBCP solutions in sol phases were free
flowing liquids which could be injected through a 25-gauge needle. The immediate thermal
gelation of the MBCP solutions around body temperature and their injectability via a small-bore
needle make MBCPs particularly attractive for local drug delivery. Even though several
mechanisms have been proposed for the description of thermal gelation of block copolymer
solutions, the mechanism based on ordered micelle packing has been most widely accepted9,98,99.
Based on the ordered micelle packing mechanism, PPG blocks are dehydrated at a concentration
above CMC and Pluronic® block copolymers form micelles. At this concentration, polymeric
unimers and the micelles are in an equilibrium state. As the temperature increases, this
equilibrium shifts from unimers to micelles, making the micelle volume fraction (Фm)
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considerably high. When Фm is greater than 0.53 in the case of Pluronic®, micelles come into
contact and pack themselves into ordered structures leading to gelation 100.

Figure 9: Phase diagrams of the aqueous solutions of Pluronic® P85, Pluronic® P104, MBCP-1
and MBCP-2 determined by the test tube inverting method.
Thermal gelation of MBCP solutions may be explained by the micelle packing. The solutions of
Pluronic® P85, MBCP-1 and MBCP-2 showed sol-gel-sol phase transition in a concentration
range up to 25 wt%. However, 25 wt% Pluronic® P104 solution possessed two distinct gel
phases upon sol-gel-sol-gel transition. The first gel phase of Pluronic® P104 solution ranged
from 24 to 47 oC while the second phase ranged from 70 to 80 oC. This may be due to the
formation of different liquid crystalline phases, isotropic/cubic phases at low temperature and
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multi-phases (cubic/hexagonal/lamellar) at high temperature101. Gelation temperatures of
MBCPs at which the polymer solution underwent sol-gel phase transition were different from
those of their corresponding Pluronic®. Moreover, the CGC of MBCPs determined from Figure 9
was 10 wt%, which was lower than that of their Pluronic® copolymers, 15 wt%. The lowered
CGC and altered gelation temperature after oligomerization is primarily due to extended and
enforced chain entanglements in MBCPs compared to their corresponding Pluronic®
copolymers9,102. Based on the test tube inverting method, a polymer concentration of 25 wt% was
chosen for the measurements of dynamic viscosity using falling ball method. Figure 10 shows
the dynamic viscosity changes of MBCP-1 and MBCP-2 polymer solutions with temperature.
Dynamic viscosity dramatically increased at 25 and 22

o

C for MBCP-1 and MBCP-2

respectively. In addition, the sol-gel transition temperatures determined by falling ball method
were 25.02 and 22.36 oC for MBCP-1 and MBCP-2 at 25 wt%. The transition temperatures
determined by falling ball method were consistent with those values determined by test tube
inverting method. A mere variation of 2 to 4 degrees was often observed between both the
methods. The difference may be due to a longer time for equilibration for the falling ball method
compared to the test tube inverting method. Even though the falling ball method would allow for
more accurate and reliable transition temperature, the test tube inverting method would give
better simulation of practical injection of a formulation with consideration of kinetic aspect of
the process. Figure 11 shows the micellar size change with temperature. Determined sizes of
micelles or micellar aggregates ranged 16-30 nm and 11-35 nm in diameter for MBCP-1 and
MBCP-2, respectively, at temperatures below 30 oC. The micelle sizes were slightly increased as
the temperature increased from 10 to 30 oC. However, the micelle aggregation upon a
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temperature increase from 30 to 40 oC resulted in a dramatic increase in micellar sizes to the
range of 500-700 nm.

Figure 10: Determination of dynamic viscosity changes of MBCP-1 and MBCP-2 aqueous
solutions as a function of temperature using falling ball method. The polymer concentration was
25 wt%. The MBCP solutions were equilibrated for 20 minutes at each temperature.
This indicates that the micellar aggregation is the main mechanism for sol-gel transition of
MBCP at 30-40 oC. GPC chromatograms in Figure 12 show the degradation of MBCP-2 at
different pHs. Since the degradation pattern of both MBCP-1 and MBCP-2 was similar, only the
degradation of MBCP-2 is shown here. The polymer degraded more rapidly in acidic media than
in neutral medium. The polymers were not degraded at pH 7.4 for even 40 days (GPC
chromatograph for day-40 was not shown here) data for while the complete degradation was
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observed within 4 and 18 days at pH 5.0 and 6.5, respectively. At pH 6.5, the polymer started
degrading from day 5, which coincided with the initiation time of gel erosion.

Figure 11: Determination of micellar size changes of MBCP-1 and MBCP-2 using dynamic light
scattering. The micellar size changes were measured as a function of temperature. The polymer
concentration was 4% w/v. The results represent the mean  SD for n=3.
From these results, it is evident that the multiblock copolymers were degraded into lower
molecular weight polymers. The degradation of hydrogel is generally affected by several factors
such as the number of degradable bonds in the polymer103,104, the presence of cross-links105 and
characteristics of degradable bonds84,85. The important factors for the degradation of the MBCP
polymers are presumably the number of acid-labile acetal bonds and sensitivity of acetal bond to
pH. Compared with previously reported PEG-grafted polyacetal-based polymers, MBCP
polymers were degraded faster than the graft polymer-based polymers in an acidic medium. In
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the case of PEG-grafted polyacetal gel, it takes about 40 days for polymer degradation at pH
5.084. The main reason for the faster degradation may be the fewer acetal bonds in MBCPs than
in the graft polymer.

pH 7.4

Figure 12: Gel permeation chromatograms showing MBCP-2 polymer degradation at three
different pH. The different phosphate buffers used were pH 5.0, 6.5 and 7.4. The MBCP
polymers were degraded into lower molecular weight monomers.
Because MBCPs have only 4 or 5 average acetal bonds in each polymer chain, the cleavage of
small number of acetal bonds can result in Pluronic® unimers or low-molecular weight oligomers
of which solutions have a greater CGC and/or higher gelation temperature than MBCPs.
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However,

PEG-grafted

polyacetal

should

be

significantly

degraded

before

losing

thermosensitivity. Cleavage of small number of acetal bonds in polyacetal backbones would not
considerably change the overall ratio of hydrophilicity to hydrophobicity in the PEG-grafted
polyacetal. The possible degradation products of MBCPs would be initial triblock copolymer
(PEG-PPG-PEG), and a little amount of diethylene glycol and acetaldehyde based on the
inference from an acid-labile PEG polymer with acetal bonds85. Monomeric Pluronic® molecular
weights are smaller than 60,000 which is the maximum molecular weight cleared by kidneys.
2.5. Conclusions
Novel biodegradable thermogelling polymers with pH-sensitive acetal linkages have been
synthesized from Pluronic® copolymers by a simple method. The synthesized polymers did not
cause significant cytotoxicity. The aqueous solutions of these polymers underwent gelation at
body temperature and the gelation temperature of the polymer solution was dependent on
polymer concentration and the type of Pluronic® copolymer used for the MBCP synthesis.
Micellar aggregation was observed for both MBCP polymers at body temperature. MBCP
polymers were degraded in a pH dependent fashion. At a neutral pH, polymers were stable for a
long period of time while rapid degradation was observed at acidic pHs.
“Reprinted from Acta Biomaterialia, 6, Garripelli VK, Kim JK, Namgung R, Kim WJ, Repka
MA, Jo S, A novel thermosensitive polymer with pH-dependent degradation for drug delivery,
477-485, Copyright (2010), with permission from Elsevier Limited.”
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CHAPTER-3
DRUG RELEASE FROM pH-SENSITIVE MULTIBLOCK COPOLYMER
THERMOGEL
3.1. Abstract
MBCP-2 thermogel has been proposed for sustained release of therapeutic agents. Hydrophobic
small-molecule drugs (paclitaxel (PTX) and camptothecin (CPT)) and model hydrophilic
macromolecules (FITC-dextrans of molecular weights 10, 20, 40, 150 and 250 kDa) were
successfully loaded into and released from the thermogels. Drug loaded polymer solutions were
characterized for gelation behavior and micelle size. Drug loading increased the size of the
multiblock copolymer micelles from 20 to 100 nm. The copolymer improved PTX and CPT
loading in an aqueous solution by 6900 and 1050 fold, respectively, comparing to their solubility
in water. The thermogels released loaded drugs in a pH-dependent fashion regardless of their
properties. At pH 5.0 and 6.5, PTX and CPT completely released in 4 and 15 days, respectively,
by a combined mechanism of diffusion and erosion. At neutral pH, diffusion predominated gel
erosion to sustain the drug release up to 40 days. FITC-dextran release from the thermogels
showed a similar pH-dependent trend as the hydrophobic small molecule drugs. However,
dextran release at neutral pH was entirely dependent on the molecular weight of dextrans. Low
molecular weight (10 and 20 kDa) dextrans were completely released in 12 and 21 days,
respectively, while high molecular weight (  40 kDa) dextrans being continuously released over
36 days indicating that the threshold of molecular weight necessary for sustained release of a
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hydrophilic macromolecule from this thermogel (eg: enzymes, monoclonal antibodies,
immunotoxins etc.) is 40 kDa. Taken all together, MBCP-2 thermogel showed potential as a
controlled drug delivery system that sustains the release of both hydrophilic and lipophilic
molecules.
3.2. Introduction
For the last few years, research has been directed towards developing thermogel systems which
can deliver a variety of therapeutic chemicals at a predetermined rate12,106-110. Recently, two
model drugs, vitamin B12 (VB12) and bovine serum albumin (BSA), were studied with PEGPCL-PEG triblock copolymer thermogel, which resulted in a sustained drug release (4-12 days)
with severe initial burst release at the first day107. Diffusion was the main mechanism for the
release of both drugs. Especially, hydrophilic VB12 was rapidly released from the thermogel
comparing to the BSA. Honokiol and BSA have been investigated for their release from PCLPEG-PCL thermogels108. Despite the hypothesis that thermogels can be applied for sustained
delivery of various chemicals with different physicochemical properties, they were able to
demonstrate sustained drug release only for less than 2 weeks even at polymer concentrations
high as 20, 30 wt%. Another thermosensitive hydrogel based on poly(organophosphazene)
released the incorporated FITC-dextran (Mw 71,600 Da) and human serum albumin (HAS) for
over two weeks and the drug release was entirely dependent on the polymer concentration 109.
However, from the previous findings, it should be noted that thermogelling system shows
limitation in sustained release of hydrophilic chemicals. Two different model macromolecules,
lysozyme and bromelain, were studied with polyethylene oxide/polylactic acid based copolymer
and their release from the thermogel lasted for 2-8 days110. It is reported that the bromelain was
released at a slower rate comparing to lysozyme because of its relatively hydrophobic nature
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comparing to lysozyme. The slower bromelain release than lysozyme also supported the idea that
thermogels work better with hydrophobic chemicals than hydrophilic chemicals. It is worth
mentioning OncoGel™, a thermogel formulation of PTX in ReGel® which is currently under
phase II clinical trials106. ReGel® has extended the in vitro release of insulin and porcine growth
hormone for up to 7 and 14 days, respectively, while sustaining hydrophobic PTX release over
50 days12.
Although various thermogel systems have been proposed for sustained release of therapeutics,
thus far, only limited knowledge is available for understanding the relationship between the
molecular properties associated with drugs and their release from thermogels. With the current
research work, we studied the factors associated with drugs to release nonelectrolyte model
chemicals with different molecular and physicochemical properties using MBCP-22,111,112.
MBCP-2 has been synthesized from a triblock copolymer, PEG-PPG-PEG, Pluronic® P104,
which has weak gelation and dissolution properties. However, MBCP-2 formed after
oligomerization of Pluronic® P104, showed dual-sensitivity to temperature and pH with
improved gelation, dissolution and drug release properties comparing to Pluronic® P104
thermogel.
Taken all together, the main goal of this research work is to evaluate the effects of pH of the
release media, hydrophilicity, hydrophobicity and molecular weight of the chemicals on their
release from MBCP-2 thermogel. Hydrophilic macromolecules (FITC-dextran) of different
molecular weights and hydrophobic PTX and CPT were studied as nonelectrolyte models
chemicals.
3.3. Experimental
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3.3.1. Materials
Pluronic® P104 was received from BASF chemical company (Florham Park, NJ) as a gift. PTX
and CPT were purchased from LC Laboratories (Woburn, MA) and Fisher Scientific (Pittsburgh,
PA) respectively. FITC-dextran (10, 20, 40, 150 and 250 kDa) was received from Sigma (Saint
Louis, MO). All other chemicals were obtained from Fisher Scientific (Pittsburgh, PA) and used
without further purification.
3.3.2. Synthesis of MBCP-2
Synthesis of MBCP-2 was described in Section 2.3.2.
3.3.3. DSC of polymer solutions
Polymer solutions (Pluronic® P104 and MBCP-2) were prepared in deionized water in the
concentration range 1 to 25 wt%. Samples were gently stirred at 4 °C for 12 h. Aluminum cells
were loaded with accurately weighed polymer solution (~5 mg) and reference cells were made
up with same amount of deionized water. Thermographs of the polymer solutions were recorded
on Diamond DSC (Perkin Elmer, Waltham, MA) in a temperature range of -10 to 50 °C at 5
°C/min. Before recording the thermographs, samples were thermally equilibrated at -10 °C for 15
min. Dry nitrogen at a rate of 20 mL/min was continuously supplied throughout the
measurement.
3.3.4. Thermal gelation
A solvent evaporation method was used to load PTX and CPT at 1 mg/ml in MBCP-2 solutions.
Required amount of MBCP-2 was dissolved in 200 µL of the acetone. After partial removal of
acetone by dry nitrogen flushing, 20 µL of the acetone containing 1000 µg of PTX or CPT was
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added to the polymer solution. By continuously mixing the polymer-drug mixture, acetone was
removed by dry nitrogen flushing. The mixture was vacuum dried for 12 hr to remove traces of
acetone. Later, MBCP-2-drug mixtures were dissolved in deionized water at 4 °C to achieve 10,
15, 20 and 25 wt% MBCP-2 solutions. FITC-dextran (10 mg/ml) was dissolved in MBCP-2
solutions (10, 15, 20 and 25 wt%) by simple mixing. Phase transition temperatures of MBCP-2
solutions in presence or absence of drug loading was measured using a test tube inverting
method56,113. One milliliter of MBCP-2 and MBCP-2-drug solutions were loaded into 4 mL vials
and equilibrated at 10 °C for 15 min. The sol-gel and gel-sol transitions of the polymer solutions
were tested by test tube inversions in the range of 10-80 °C and at a rate of 1 °C/5 min. Vials
were inverted and the solutions were tested based on flow or non-flow criteria for every five
minutes. Temperature at which the polymer solution stopped flowing upon the tube inversion
was considered as the gelation temperature of the particular concentration.
3.3.5. DLS
PTX and CPT were loaded in MBCP-2 solutions (0.5, 0.7, 0.9, 1.0, 2.0 and 4.0 wt%) at a
concentration of 300 µg/mL by the solvent evaporation method described in previous section.
Drug free MBCP-2 micelles were also prepared at the same concentrations. The polymer
solutions were mixed at 4 °C for 24 h. Later, the solutions were filtered through 0.45 µ syringe
filter to remove undissolved particles. Finally, the size of the empty and drug loaded micelles
was measured using Zetasizer Nano ZS (Malvern Instruments, Malvern, UK) at 25 °C.
3.3.6. Transmission electron microscopy (TEM)
MBCP-2 micelles (1 wt%) were loaded with PTX or CPT at a concentration of 300 µg/mL by
the solvent evaporation method. The polymer solutions were kept at 4 °C for overnight to
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disperse the micelles in water. Later, the solutions were filtered through 0.45 µ syringe filter to
remove any undissolved particles. The filtered solutions were transferred onto hydrophilictreated grids, which were then rinsed with deionized water. Excess water was removed with filter
paper and the grids were left overnight in vacuum oven for complete dryness. Finally, the
samples were imaged by TEM (Hitachi-7600) operated at an acceleration voltage of 80 kV.
3.3.7. Release of hydrophobic drugs
PTX and CPT were incorporated in MBCP-2 gels (25 wt%) at 1.00 mg/mL and 0.75 mg/mL
respectively, by the solvent evaporation method. One milliliter of drug loaded MBCP-2 solution
was placed in each 15 mL amber colored vial and allowed for gelation by incubation at 37 °C for
15 min. Eight milliliters of phosphate buffer (pH 5.0, 6.5 and 7.4; 50 mM; 1 wt% Tween 80)
were added on top of the gels in each vial. While incubating at 37 °C, release media were
completely replaced with fresh media at different time intervals to maintain perfect sink
conditions for both drugs113. Concentration of the released PTX and CPT was determined by
high performance liquid chromatography (HPLC). HPLC was run on a Waters system (Waters,
Milford, MA) equipped with a binary pump, a dual absorbance detector, and a Symmetry® C18
column (150 × 4.6 mm I.D.; 5 µm particle size). For the detection of PTX, mobile phase
composed of methanol and water at a ratio of 70:30 was eluted at a flow rate of 0.8 mL/min at 25
o

C. The dual absorbance detector was set to 230 nm. In case of CPT detection, methanol and

water at a ratio of 55:45 was eluted at a flow rate of 1.0 mL/min at 25 oC. Wavelength for the
detection of CPT was 254 nm. Also, the retention times of PTX and CPT were 7.2 and 6.8 min
respectively. Calibration curves for PTX and CPT (Figure 13) at pH 5.0, 6.5 and 7.4 were
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Figure 13: Calibration curves for PTX at pH 5.0 (A), 6.5 (C) and 7.4 (E); CPT at pH 5.0 (B), 6.5
(D) and 7.4 (F).
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Figure 14: Calibration curves for FITC-Dextrans with various molecular weights such as 10
kDa (A), 20 kDa (B), 40 kDa (C), 150 kDa (D) and 250 kDa (E) in pH 5.0.
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Figure 15: Calibration curves for FITC-Dextrans with various molecular weights such as 10
kDa (A), 20 kDa (B), 40 kDa (C), 150 kDa (D) and 250 kDa (E) in pH 6.5.
48

Figure 16: Calibration curves for FITC-Dextrans with various molecular weights such as 10
kDa (A), 20 kDa (B), 40 kDa (C), 150 kDa (D) and 250 kDa (E) in pH 7.4.
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plotted using peak area of the drug versus drug concentration. Such calibration curves were used
to calculate drug concentration in the samples.
3.3.8. Release of hydrophilic model drugs
FITC-dextran (10, 20, 40, 150 and 250 kDa) at a concentration of 10 mg/ml was dissolved in 25
wt% MBCP-2 solution with stirring at 4 °C. The polymer solutions (1 mL) were loaded in amber
color vials and allowed for gelation at 37 °C for 15 min. Two milliliters of citric buffer (pH 5.0;
50 mM) or phosphate buffer (pH 6.5 and 7.4; 50 mM) were added on top of the gels. While
incubating at 37 °C with periodic medium changes, samples were collected at different time
intervals. Samples were analyzed using UV-visible spectrophotometer at 455 nm. Calibration
curves for FITC-dextran at pH 5.0, 6.5 and 7.4 (Figure 14, 15 and 16) were plotted using the
absorbance at 455 nm versus drug concentration. Such calibration curves were used to calculate
FITC-dextran concentration in the release samples.
3.3.9. Data analysis and statistics
Student‟s t-test was used to perform the statistical comparison. A probability value less than 0.05
was considered significant. An add-in program, DDSolver, was used to compute the similarity
factors for the drug release from thermogels114. Release profiles with similarity factor greater
than 50 were considered similar115.
3.4. Results and Discussion
MBCP-2 solutions presented sol-gel-sol transition upon a temperature increase and gelation
temperature was dependent on polymer concentration. In addition, oligomerization of Pluronic®
P104 resulted in MBCP-2 with clinically acceptable gelation properties. A broad gelation
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window comparing to Pluronic® P104 was observed for MBCP-2. Being amphiphilic in nature,
MBCP-2 self assembled to generate polymeric micelles and, therefore, micellization process has
been studied calorimetrically. Micellization is an endothermic process which can be
characterized by a transition in a DSC thermograph116. Onset temperature at which micelles start
to form is considered as CMT at the particular concentration. CMT values of Pluronic® P104 and
MBCP-2 solutions are provided in Figure 17.

Figure 17: Determination of CMT values of Pluronic® P104 and MBCP-2 solutions by DSC. The
CMT values represent the mean ±SD of three experiments.
With increase in polymer concentration, CMT values decreased gradually for Pluronic® P104
and MBCP-2. These changes are in complete accordance with previously reported trend for
Pluronic® P10497,117. It is evident from the data that the CMT values of MBCP-2 were slightly
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lower than Pluronic® P104, which is mainly due to the increased molecular weight of MBCP-2
comparing to Pluronic® P104, as high molecular weight Pluronic® copolymers are known to
favor easy self assembly comparing to the low molecular weight polymers with the similar
hydrophobic to hydrophilic ratio97.

Figure 18: Sol-gel-sol transition phase diagram of MBCP-2 solutions in presence of PTX (1000
µg/mL). The results represent the mean ±SD for n=3.
Additives are known to exert special effects on the gelation process of the thermosensitive
polymers. Gelation temperature of a thermosensitive polymer solution can be tuned by the
addition of different agents such as NaCl, NaSCN and glucose11,107. Therefore, it is imperative to
study the effect of loaded drugs such as PTX, CPT and FITC-dextran on the gelation process of

52

MBCP-2. At the concentrations employed for in vitro drug release study, none of the loaded
drugs showed a noticeable effect on the sol-gel-sol transition of MBCP-2 solutions. This may be
due to the fact that the drug concentrations used for gelation study are not high enough to
produce such an effect. However, in Figure 18, a slight shift in the MBCP-2 gelation curve is
observed upon the addition of PTX which is believed to be an effect induced by alterations of
inter-micellar interactions 118.
Table 2: Determination of micelle size of MBCP-2 in presence or absence of PTX and CPT using
DLS. The results represent the mean ±SD for n=3.

Micelle size (nm)

MBCP-2
concentration
(wt%)

MBCP-2 micelles

PTX loaded MBCP-2
micelles

CPT loaded
MBCP-2 micelles

0.5

25.3 (±7.0)

36.7 (±6.7)

69.4 (±4.2)

0.7

27.0 (±3.6)

71.3 (±5.1)

81.1 (±4.7)

0.9

25.0 (±13.2)

69.4 (±11.1)

80.1 (±4.7)

1

37.7 (±10.0)

69.7 (±3.5)

94.8 (±13.8)

2

35.0 (±5.7)

87.7 (±3.5)

99.9 (±5.5)

4

30.7 (±4.9)

85.0 (±12.3)

90.3 (±4.9)

As micelle formation plays a key role in the gelation process of MBCP-2111, micelle size was
measured in presence of loaded drugs using DLS. Table 2 shows the variation in MBCP-2
micelle sizes in presence or absence of PTX and CPT. Mean diameter of plain micelles was
between 20-40 nm, while the sizes of drug loaded micelles were 40-100 nm indicating that drug
loading prominently increased micelle size. To support DLS data, the micelles were also
visualized by TEM and the observed sizes of the micelles in Figure 19 were ~40, ~70 and ~100
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nm for MBCP-2, PTX loaded MBCP-2 and CPT loaded MBCP-2 respectively, at a MBCP-2
concentration of 1 wt%. Micelle sizes observed in TEM images were similar to the values
obtained from DLS indicating that there is a good correlation between TEM and DLS data for
MBCP-2.

Figure 19: TEM images of micelles of A) Pluronic® P104, B) MBCP-2, C) PTX-loaded MBCP2 and D) CPT-loaded MBCP-2 at 1 wt% polymer concentration.
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Apart from drug loaded micelles, an important observation was made for drug free micelles of
Pluronic® P104 and MBCP-2. The sizes of Pluronic® P104 and MBCP-2 micelles were found to
be 16.6 (±0.3) and 37.7 (±10.1) nm respectively, at 1 wt% using DLS. A significant (P=0.03)
increase in the micelle size of MBCP-2 comparing to Pluronic® P104 was observed, which is
also confirmed by TEM images. This is mainly due to the increase in the molecular weight of
MBCP-2 (Mw: 40210 Da) upon the oligomerization of Pluronic® P104 (Mw: 9880 Da)111.

Figure 20: PTX and CPT loading in water in presence of MBCP-2. The aqueous solubilities of
PTX and CPT are 0.3 and 1.3 µg/mL respectively. The loading efficiencies of both drugs
increased linearly with increase in MBCP-2 concentration. The results represent the mean ±SD
for n=3.
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Based on the phase transition and the dynamic viscosity measurements111, an optimum polymer
concentration (25 wt%) was selected for drug release study. Under refrigerated conditions, the
polymer solution (25 wt%) was a freely flowable liquid which can pass through a 22-guage
needle warranting facile administration into the body. Also, the polymer solution quickly (<1
min) turned to gel upon a temperature increase to 37 °C. Injectability at low temperature and
rapid gelation at body temperature demonstrates the clinical applicability of MBCP-2 as a local
drug delivery system.
In vitro drug release from the thermogel was studied for lipophilic and hydrophilic drugs. In case
of lipophilic drugs, two anti-cancer chemicals such as PTX and CPT were chosen to study the
release at pH 5.0, 6.5 and 7.4. PTX and CPT are strong anti-tumor drugs but the therapeutic
efficacy of both drugs has been limited by low solubility in water and potential systemic sideeffects119,120. Current MBCP-2 thermogel system would overcome such problems by local
administration of drugs directly into tumor. As MBCP-2 was already shown to form micelles in
water, PTX and CPT loading efficiencies in MBCP-2 solution were expected to increase. Figure
20 shows the improvement in loading of PTX and CPT in water in presence of MBCP-2.
Aqueous loading of both drugs increased with increase in polymer concentration. At 25 wt%
MBCP-2, PTX and CPT were loaded at 2070.90 and 1374.90 µg/mL respectively, in water.
Nearly 6900 and 1050 fold increases comparing to the aqueous solubility of PTX (0.30
µg/mL)8,113 and CPT (1.30 µg/mL)121 respectively, were achieved. A concentration (1.00 mg/mL
for PTX and 0.75 mg/mL for CPT) below the solubility of PTX and CPT at 25 wt% MBCP-2
was chosen for in vitro drug release study. Release profiles in Figure 21 indicate that the drug
release is greatly dependent on the pH of the medium. Both drugs released from the thermogels
in nearly 4, 15 and 40 days at pH 5.0, 6.5 and 7.4 respectively.
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Figure 21. In vitro release of (a) PTX and (b) CPT from MBCP-2 thermogels at pH 5.0, 6.5 and
7.4. PTX and CPT were loaded at 1 mg/mL and 0.75 mg/mL respectively, in 25 wt% MBCP-2
thermogel. The results represent the mean ±SD for n=3.
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In vitro release profiles were in accordance with MBCP-2 degradation reported previously111.
MBCP-2 degraded in 4 and 18 days at pH 5.0 and 6.5 respectively, where as it showed minimum
or no degradation at pH 7.4 for 40 days. In an acidic pH 5.0, polymer degraded and released the
loaded drug rapidly. It is evident that the release at pH 5.0 is predominantly erosion controlled
while the release at pH 6.5 is both diffusion and erosion controlled. Most importantly, diffusion
was the main mechanism responsible for drug release at neutral conditions. Also, to better
understand the release profiles, the data were fitted to the Ritger-Peppas equation122-124:
Mt/M∞=ktn

(1)

where Mt/M∞ is fractional release of the loaded drug at time t, k is a kinetic constant and n is a
release exponent that indicates drug release mechanism. An n value less than 0.5 suggests
Fickian diffusion while an n value greater than 1.0 indicates surface erosion based release. In
addition, an n value between 0.5 and 1.0 indicates a release based on both mechanisms.
Table 3: Release kinetics of PTX and CPT from MBCP-2 thermogels at pH 5.0, 6.5 and 7.4.
Kinetic parameters were calculated using Ritger-Peppas model.

Drug
PTX

CPT

Ritger-Peppas model

pH of the release
medium

n

k (h-n)

r2

5.0

1.126

0.008

0.973

6.5

0.762

0.008

0.953

7.4

0.498

0.014

0.916

5.0

1.416

0.005

0.941

6.5

0.730

0.012

0.954

7.4

0.493

0.019

0.934
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Table 3 shows the kinetic parameters (n, k and r2) for PTX and CPT release at pH 5.0, 6.5 and
7.4. As showed in the table 3, n values for release profiles at pH 5.0 were greater than 1.0,
indicating surface erosion based release. In addition, profiles at pH 6.5 showed a release based
on both diffusion and erosion (n: ~0.7). Finally, the n values for release profiles at pH 7.4 were
less than 0.5, confirming diffusion based release. A unit drop in the pH of the media showed a
marked increase in polymer degradation and drug release and a similar effect is expected even in
a biological setting. A slight change in biological pH caused by a disease should be adequate to
trigger drug release from thermogel. The findings imply that the pH of the release medium
played an important role in the drug release, which can be translated into polymeric drug
delivery systems that locally administer drugs in response to biological pH changes. Especially
in cancer conditions, a significant drop in the pH of the extracellular tumor fluid is often
observed. Depending on the type and intensity of the tumor, extracellular pH can go down to
6.586,88. In such conditions, the thermogel is expected to respond to pH variations and self
regulate the drug release depending on the disease intensity.
To investigate drug release behavior for hydrophilic drugs, FITC- dextrans of different molecular
weights (10, 20, 40, 150 and 250 kDa) were loaded into MBCP-2 thermogels. Fluorescent
labeled dextrans are commercially available in different molecular weights and they provided a
good model for studying a size based drug release from MBCP-2 thermogel. Release profiles of
FITC-dextran at pH 5.0, 6.5 and 7.4 are shown in Figure 22. FITC-dextran release was
completed within 2 and 9 days at pH 5.0 and 6.5, respectively. As expected, at low pH, dextran
release was relatively swift comparing to pH 7.4. However, it is quite interesting to note the data
at pH 7.4, as different dextrans released from the thermogel differently. The release at pH 7.4
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clearly answers the question: what is the optimum molecular weight of the hydrophilic drug that
can be

Figure 22: In vitro release of FITC-dextran (10, 20, 40, 150 and 250 kDa) from MBCP-2
thermogels at (a) pH 5.0, (b) pH 6.5 and (c) pH 7.4. FITC-dextran was loaded at 10 mg/mL in 25
wt% MBCP-2 thermogel. The results represent the mean ±SD for n=5.
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released from MBCP-2 thermogel in a sustained manner? At the neutral pH, dextrans of
molecular weight 10 and 20 kDa were completely released in 12 and 21 days respectively.
However, dextrans of molecular weight greater than 40 kDa were released for 36 days. Also, to
confirm the similarity between the release profiles, similarity factor (f2) of the release profiles
were computed comparing to the release profile of 40 kDa dextran and the values are provided in
table 4. It is generally accepted that release profiles with f2 values between 50 and 100 are
considered similar115. The f2 values of release profiles of 150 kDa and 250 kDa were greater than
50 whereas the f2 values of release profiles of 10 kDa and 20 kDa were less than 50 when
compared with the release profile of 40 kDa. This clearly implies that the release of 40, 150 and
250 kDa are similar among all the released FITC-dextrans. For a better understand of the release
profile at pH 7.4, the data were fitted to the Ritger-Peppas equation (equation 1). Table 4 shows
the kinetic parameters (n, k and r2) for FITC-dextran release at pH 7.4.
Table 4: Release kinetics of FITC-dextrans from MBCP-2 thermogels at pH 7.4. Similarity
factors were calculated for all the release profiles comparing to the release profile of 40 kDa.

Ritger-Peppas model

Fick's second
law

n

k (h-n)

r2

D (µm2/s)

10 kDa

0.541

0.062

0.984

499.061

15.3

20 kDa

0.575

0.035

0.969

303.552

23.7

40 kDa

0.591

0.014

0.982

134.979

-

150 kDa

0.604

0.011

0.987

121.437

70.3

250 kDa

0.612

0.009

0.978

119.710

57.1

Molecular
weight of
FITC-dextran
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Similarity
factor (f2)

From the data it is evident that the n values are between 0.5-0.6 showing that both diffusion and
erosion were responsible for drug release. However, it can be assumed that diffusion has more
influence on drug release comparing to surface erosion, since n values are close to 0.5. In
addition, n values increased with increase in molecular weight of the dextran, meaning that small
molecular weight dextrans are more affected by diffusion comparing to large dextrans. A closer
analysis of the k values indicates that there was a gradual drop in the release rates on increase in
the size of the loaded dextran, which implies that the movement and release of the dextran
molecules are restricted by their size and the mesh size of the hydrogel122. Also, to gain an
insight into the diffusion coefficients of FITC-dextrans, release data were fitted to early-time
approximation equation of Fick‟s second law123. Fick‟s second law equation:
Mt/M∞=4(Dt/δ2)1/2

(2)

where Mt/M∞ is fractional release of dextran at time t, D is a diffusion coefficient and δ is
diffusional distance (thickness of the gel: 6000 µm). D values are provided in table 3 and not
surprisingly, the diffusion coefficients decreased with increase in dextran molecular weight,
which is in complete accordance with the data published by Censi et al.122. According to their
findings, the size of the loaded protein molecule has a significant role in controlling the drug
release from thermogel. MBCP-2 thermogel was able to sustain the release of high molecular
weight dextrans whereas in case of small molecular weight dextrans, thermogel was not able to
retain the loaded drugs long enough to sustain their release.
Taken all together, dextran release essentially draws a conclusion that the minimum molecular
weight necessary for a hydrophilic drug to sustain its release from MBCP-2 thermogel is 40 kDa.
MBCP-2 is a suitable candidate for controlled delivery of therapeutic proteins such as
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monoclonal antibodies, immunotoxins and enzymes with molecular weight equal to or greater
than 40 kDa. The thermogel system would not be limited to the delivery of therapeutic proteins,
but would also have applications for small molecule drugs for a sustained drug therapy. Also, the
knowledge obtained from the current findings can be useful in the development of novel
biomaterials intended for drug delivery applications.
3.5. Conclusions
A pH sensitive multiblock copolymer thermogel has been developed for local delivery of
hydrophilic and hydrophobic drugs. Micellization of MBCP-2 was studied thermodynamically
using DSC. Formation of MBCP-2 micelles and drug loading into the micelles was confirmed by
DLS and TEM. Hydrophilic drugs were loaded into the thermogels by simple mixing whereas
hydrophobic drugs utilized a solvent evaporation technique for drug incorporation. Thermogels
released the loaded drugs in a pH-dependent fashion. Especially, release of hydrophilic drugs
from the thermogels was dependent on the molecular weight of the loaded drug. A molecular
weight of 40 kDa or above is necessary for a sustained release of hydrophilic macromolecules
from MBCP-2 thermogels. The relationship between the physicochemical properties of the drugs
and their release from thermogel has been better explained. Furthermore, the current system
would provide a platform for the sustained delivery of small molecule drugs as well as large
molecule proteins.
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CHAPTER-4
NANOCOMPOSITE THERMOGEL FOR CONTROLLED RELEASE OF SMALL
PROTEINS

4.1. Abstract
A NCT comprised of Pluronic®-based multiblock copolymer (MBCP-2) and laponite (LA)
nanoclay has been developed for sustained delivery of low molecular weight (LMW) proteins.
Rapid release of LMW proteins from MBCP-2 thermogel has been a problem for sustained drug
delivery. We overcome the limitation by delivering the proteins using NCT approach. Lysozyme
(Mw: 14700 Da), a relatively LMW protein, was successfully loaded into and released from NCT.
In addition, interactions among MBCP-2, laponite and lysozyme were studied in terms of
gelation, micellization, particle size and zeta potential. Micellization process of the composite
solutions was monitored using DSC. CMTs and sol-gel transition temperatures of MBCP-2
solutions lowered on laponite addition. Positively charged lysozyme adsorbed onto anionic
surfaces of laponite and the amount of adsorption increased with increase in lysozyme
concentration. Particle size and zeta potential of laponite-lysozyme complex were also dependent
on lysozyme concentration. Finally, NCT sustained lysozyme release to 40 days whereas
lysozyme release from MBCP-2 thermogel lasted for only 18 days. The structural stability of
released lysozyme was confirmed by CD spectroscopy and DSC.
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4.2. Introduction
Designing of polymer-nanoclay based composite thermogels would be a beneficial approach for
sustained delivery of therapeutics. A synergistic improvement in the characteristics of composite
thermogels can be attained by combination of nanoscale properties of the clays with adjustable
physico-chemical properties of thermosensitive polymers. Thermogels enable simple
administration of therapeutic agents via spontaneous depot formation at body temperature56,111113,125-127

. Nanomaterials located inside a 3D supramolecular network of thermogels can alter and

even sustain the delivery of loaded therapeutics128,129. Among variety of natural and synthetic
nanomaterials available, smectite clays have been widely studied for drug delivery
applications130-133.
LA, a synthetic smectite nanoclay, is a layered magnesium silicate and it exists as nanoscale
disks (25 nm diameter x 1 nm thickness). LA is composed of octahedrally arranged magnesiumoxygen-hydroxide sheets and tetrahedrally coordinated silicon-oxygen layers133. Together with
appealing structure, LA holds measurable negative surface charge, which mainly arises from
isomorphic substitution of some magnesium cations with lithium and presence of some vacant
positions133. Possessing in-built surface charge (charge density: 0.014 e/Å2), well-defined
architecture and large surface area for adsorption (~ 350 m2/g), it has been possible to utilize LA
in various drug delivery applications133,134. Also, recent studies show the compatibility of LA
towards different cells, indicating its potential for drug delivery applications135,136. Another
interesting property of LA is to intercalate small molecule drugs between inter layer spaces of
platelets132,133. Intercalation has significantly improved the solubility of a hydrophobic drug,
itraconazole, and sustained its release132. Similar results were reported for another small
molecule drug, donepezil, proving LA‟s ability to load and release drugs for sustained delivery
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applications133. Pawar et al. studied the binding of macromolecular protein chains to charged
surfaces of LA134. Gelatin A preferentially bound to anionic surfaces of LA where as gelatin B
bound to both surface and edges. Even though the main focus of their research was to study
protein-LA interactions, the findings provided valuable information which could be translated
into the development of drug delivery systems.
Several research groups studied the interactions between LA and Pluronic® copolymers137-140.
Pluronic®, a triblock copolymer of poly(ethylene glycol)-poly(propylene glycol)-poly(ethylene
glycol), has been successfully applied as an injectable gel for local drug delivery
applications13,141,142. Pluronic® solutions exhibit a thermal gelation by reversible micellar
aggregation. It was shown that, at high polymer concentrations, addition of LA would disrupt
thermal gelation137. On the other hand, Sun et al. achieved thermal gelation at low Pluronic®
concentrations with sufficiently high LA concentrations139. In this case, the self-assembling
properties of LA warranted the gelation of Pluronic® solutions at relatively low polymer
concentrations. In another situation, gelation was induced by light-activated assembly of LA
particles in presence of a photoacid generator138. Even though, several interesting findings were
reported on LA-Pluronic® interactions, none of these composite systems were applied for drug
delivery applications. Recently, a Pluronic® F127-LA composite thermogel was shown to sustain
the release of albumin comparing to Pluronic® gel alone140. LA incorporation significantly
altered albumin release from the thermogel. Even though the system presented a sustained
release, it was only limited to several days mainly because of the instability of Pluronic® gel.
Moreover, high concentrations (3 wt%) of LA were employed to achieve such a release effect.
Here we developed a NCT consisting of Pluronic® P104-based MBCP-2111 and LA with an
intention to sustain the release of LMW proteins over several weeks. Previously, MBCP-2
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sustained the release of model proteins (FITC-dextrans) with molecular weight above 40 kDa143.
We hypothesize that adsorption of LMW cationic proteins onto anionic surfaces of LA would
sustain their release from thermogel. Lysozyme (LY) was used as a model hydrophilic drug to
verify the hypothesis. Additionally, interactions among MBCP-2, LA and LY were also
investigated.
4.3. Experimental
4.3.1. Materials
Laponite RD was purchased from Southern Clay Products (Gonzales, TX). Pluronic® P104 was a
gift from BASF chemical company (Florham Park, NJ). Chicken egg white LY was obtained
from Sigma (St. Louis, MO). All other chemicals were purchased from Fisher Scientific
(Pittsburgh, PA) and used without further purification.
4.3.2. Synthesis of MBCP-2
MBCP-2 synthesis was described in chapter 2.3.2.
4.3.3. Thermal gelation
LA stock solution (1 wt%) was prepared by dispersing required amount of LA in deionized
water (DW). The dispersion was mixed and sonicated for 12 hr and filtered through a 0.45 µ
filter to remove dust particles. MBCP-2 was dissolved in DW at 5 °C and mixed for 24 hr at the
same temperature. MBCP-2-LA and LA-LY solutions were prepared by mixing appropriate
amounts of stock solutions at 5 °C. Also, MBCP-2-LA-LY composites were prepared by mixing
MBCP-2 and LA-LY solutions. Composite solutions (1 mL) were loaded into 4 mL vials and
equilibrated at 8 °C for 15 min. A test tube inverting method was used to measure phase
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transition temperatures of test solution in the range of 8-50 °C56,113. Sample vials were heated at
a rate of 0.2 °C/min. Vials were inverted and tested based on flow or non-flow criteria for every
five minutes. The temperature at which the polymer solution stopped flowing upon the tube
inversion was considered as the gelation temperature.
4.3.4. DSC of composite solutions
MBCP-2-LY composite solutions were prepared by the method described in previous section.
After 12 hr incubation at 4 °C, samples were accurately weighed (~ 7 mg) and loaded into
aluminum cells. Also, reference cells were charged with same amount of DW. Thermographs of
composite solutions were recorded on Diamond DSC (Perkin Elmer, Waltham, MA) in a
temperature range of -10 to 50 °C at 5 °C/min. Before recording the thermographs, samples were
thermally equilibrated at -10 °C for 5 min. Dry nitrogen at a rate of 20 mL/min was continuously
supplied throughout the measurement.
4.3.5. DLS
Interactions between LA and LY were studied using DLS. LA-LY mixtures were prepared by
mixing LA and LY stock solutions for 1 hr. The mixtures were sonicated for 5 min, filtered
through 0.45 µ syringe filter and measured for particle size and zeta potential using Zetasizer
Nano ZS (Malvern Instruments, Malvern, UK) at 25 °C.
4.3.6. LY release from the thermogels
LA-LY complex was prepared by mixing 250 µL of LY (8 mg/mL in DW) and 500 µL of LA
solution (2 wt%) for 30 min. To LA-LY complex solution, 250 µg of MBCP-2 was added and
the solution was mixed for 12 hr at 4 °C. The final concentrations of MBCP-2, LA and LY in the
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composite solution were 25 wt%, 1 wt% and 2 mg/mL respectively. The composite solution was
charged into 4 mL vial and the loaded vials were equilibrated at 37 °C for 15 min to form NCTs.
LA free thermogels were prepared in the similar method. Phosphate buffer (2 mL, pH 7.4, 50
mM) was added on top of the thermogels to release LY. Release medium was fully replaced with
fresh buffer at predetermined time intervals. The amount of released LY was determined by
micro-BCA protein assay144. A calibration curve for LY (Figure 23) was plotted using the
absorbance at 540 nm versus LY concentration.

Figure 23: Calibration curve for LY at pH 7.4 developed using BCA protein assay.
4.3.7. Structural stability of released LY
CD spectroscopy and DSC were used to study the stability of LY in the release media145,146. CD
spectra of native LY and LY in the release media were recorded in the wavelength range 250-
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190 nm on a CD spectrometer (Olis® DSM 20 CD Spectrophotometer, Bogart, GA). LY in the
release media was collected by freeze drying the release samples. LY was diluted with phosphate
buffer (pH 7.4, 50 mM) to achieve concentrations in the range of 0.01-0.05 mg/mL. A cuvette
(path length: 1 mm) was loaded with sample solution and CD spectra were recorded at room
temperature. Sample cell compartment was purged with nitrogen at a flow rate of 15 mL/min.
Molar ellipticity of the samples was calculated after a blank reference of phosphate buffer was
subtracted from the raw data. DSC of lyophilized LY was run in the temperature range of 0-250
°C at a rate of 10 °C/min. Samples were equilibrated at 0 °C for 5 min before the scanning.
4.3.8. Data analysis and statistics
Results are expressed as mean ±SD, where applicable. Student‟s t-test was used for statistical
comparison. A probability value less than 0.05 was considered significant.
4.4. Results and discussion
Interactions between LA and Pluronic® co-polymers have been extensively studied by various
research groups137,139,140. Depending on concentration, temperature and type of Pluronic® used,
LA and Pluronic® aqueous mixtures generate either nanocomposite hydrogels or liquid
dispersions. Since phase transition temperature is an important criterion for practical drug
delivery application of a thermosensitive polymer, studying the effect of LA incorporation on
sol-gel transition of MBCP-2 was imperative. For easy administration into body, quick gelation
at physiological temperature and a sustained drug release, MBCP-2 required to be employed
above 20 wt%111,143. Therefore, effect of LA addition on gelation was studied at high polymer
concentrations and the data is shown in Figure 24.
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Figure 24: Sol-gel transition temperatures of MBCP-2-LA composite solutions as a function of
LA concentration. Two MBCP-2 concentrations (20 and 25 wt%) were tested. *Significant
difference from the sol-gel transition temperature of MBCP-2 (25 wt%) at 0 wt% LA (p < 0.05).
**Significant difference from the sol-gel transition temperature of MBCP-2 (20 wt%) at 0 wt%
LA (p < 0.05). The results represent the mean  SD for n=3.
Increasing LA addition gradually lowered the gelation temperature at particular MBCP-2
concentration. It was also observed that a minimum LA concentration was necessary to induce a
change in the gelation temperature. For example, addition of LA at 2.5 wt% lowered the gelation
temperature of polymer solution (25 wt%) by ~16 °C. Also, the minimum concentration of LA
required to produce a noticeable change in gelation process was 1 wt%. This shows that gelation
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properties of charged LA particles played an important role in the phase transition of
nanocomposite solutions.

Figure 25: Sol-gel transition temperatures of MBCP-2-LA-LY composite solutions as a function
of LY concentration. MBCP-2 solutions (25 wt%) at 1 wt% LA were tested.
Usually, low Pluronic® concentrations are used to inhibit or slow down the gelation process of
LA by sterically stabilizing LA particles through preferential adsorption of hydrophobic PPO
segment onto LA surface and free dangling of PEO segment into the solution 139,147. On the other
hand, addition of small amounts of LA promotes the gelation of Pluronic® solution, which is
evident by recent work of Wu et al140. Therefore, a careful optimization of the compositions of
MBCP-2 and LA would result in a nanocomposite with desirable viscosities at low temperatures
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and favorable gelation properties for drug delivery at physiological temperatures. The gelation
temperatures of MBCP-2 solutions (25 wt%) were also measured in presence of LY coated LA
and the data is showed in Figure 25. Since the adsorption of LY on LA alters the charge on LA
surface, it was expected that the LY adsorption would change the gelation temperatures of
MBCP-2-LA composite solutions. Surprisingly, the sol-gel transition temperatures of MBCP-2
solutions didn‟t change upon the addition of LY adsorbed LA.

Figure 26: Determination of CMT values of MBCP-2-LA composite solutions by DSC.
*Significant difference from CMT of MBCP-2 (25 wt%) at 0 wt% LA (p < 0.05). **Significant
difference from CMT of MBCP-2 (20 wt%) at 0 wt% LA (p < 0.05). The values represent the
mean ±SD of three experiments.

73

Furthermore, to better understand the gelation, the process was studied calorimetrically using
DSC. Micellization is an endothermic process and it is often possible to study the self assembly
of polymers in water using calorimetry113,117. The on-set temperature of an endothermic event in
a thermograph is often considered as CMT at the particular polymer concentration. The CMT
values of the composite solutions were shown in Figure 26. Since gelation of MBCP-2 solution
was affected by the addition of LA, a similar effect on CMT of polymer solution was expected.
All composite solutions showed broad endotherms in the temperature range of 2-20 °C.
Importantly, CMT of MBCP-2 solutions decreased gradually on increasing LA concentration. In
addition, effect of LA on 25 wt% polymer solution was more pronounced comparing to 20 wt%
as shown in Figure 24. It is believed that the initiation of micellization at low temperature in
presence of LA would be the main reason for lowering of the gelation temperature of MBCP-2
solution. Contrary to our findings, Boucenna et al. did not see a change in CMT values of
Pluronic® F127 (16 wt%) on the addition of LA (0-3 wt%)137. This may be due to high molecular
weight of MBCP-2 (Mw measured using GPC: 40210 Da) comparing to Pluronic® F127 (Mw
provided by BASF: 12500 Da) and difference in PEG/PPG value for MBCP-2 (0.67) and
Pluronic® F127 (2.33)111,147. According to Nelson et al., adsorption of Pluronic® onto LA surface
is highly dependent on total molecular weight of the polymer and molecular weight of PEO or
PPO blocks147.
Particle size and zeta potential of LA in presence of different concentrations of LY were shown
in Figure 4. LY has an isoelectric point value of 10.5 with net positive charge on the protein
surface at experimental conditions148.
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Figure 27: Particle size and zeta potential of LA-LY complex as a function of LY concentration
measured using DLS. The results represent the mean  SD for n=3.
It has been reported that the surface of LA has good binding capacity for polyampholyte protein
molecules134. Therefore, strong interactions between positively charged LY and negatively
charged surfaces of LA are expected at neutral pH. Scheme in Figure 28 has been proposed to
explain DLS data. According to DLS, LA has particle size of 293.8(±23.9) nm and zeta potential
of -49.9(±4.7) mV. It has been known that LA forms dimers, trimers, oligomers, and even
tactoids in the solution149,150. Therefore, the presence of large particles in LA solutions is not
surprising because more than one LA particle can aggregate and produce large particles
comparing to pristine LA (~40 nm)133 as shown in Figure 28a. At low LY concentration (0.025
wt%), particle size (414.7(±90.1) nm) and zeta potential (-36.5(±5.3) mV) of LA-LY were
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slightly but significantly (p<0.05) greater than LA alone indicating that LY moderately covered
the surfaces of LA and increased the zeta potential and particle size of the complex as suggested
in Figure 28b. Complex formation at 0.1 wt% of LY resulted in a zeta potential of ~10 mV and
maximum particle size of 1028.9 (±47.2) nm. At this weight ratio (Figure 28c), the solution
seemed to have enough LY to shield the charge on LA surface. Eventually, masking surface
charges has resulted in the formation of even larger aggregates of complex in the solution.
However, it is interesting to observe the particle size and zeta potential values of complexes at
LY concentrations above 0.1 wt%. Particle size of the complex decreased gradually and reached
a constant value (~150 nm) and zeta potential increased to a maximum (~30 mV) on increasing
LY concentration. At high LY concentrations, it is believed that protein molecules were able to
intercalate between interlayer spaces of LA and separate the aggregates into small size LA-LY
complexes as represented in Figure 28d.
Recent studies also suggested the possibility of increase in interlayer spaces of LA by
intercalation of small molecule drugs such as itraconazole and donepezil132,133. Being a high
molecular weight protein, LY could exert even stronger forces comparing to small molecules to
alter the spatial arrangement of LA. In addition to particle size, zeta potential values increased
with increasing LY concentration, which is in complete accordance with the data presented for
montmorillonite, a nanoclay with negative surface charge similar to LA151.
Furthermore, the concentration dependent adsorption was studied by measuring the amount of
LY adsorption on LA (Figure 29). LY adsorption was only slightly increased with increase in LY
concentration below 0.1 wt% LY. However, a drastic increase in the LY adsorption was noticed
above 0.1 wt% LY. This could be related to increase in surface area of LA available for LY
adsorption. As indicated in DLS data, sharp decrease in particle size above 0.1 wt% resulted in
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increase in the surface area of LA and adsorption of LY as well. Cationic molecules adsorb onto
negatively charged surfaces in remarkably high quantities, which is evident by recent studies on
polycation adsorption on montmorillonite151. As reported, relatively high quantities of LY (upto
3.5 mg/mL) were adsorbed onto LA surface (0.5 mg/mL). Taken all together, a good correlation
was observed between DLS and LY adsorption data.

Figure 28. Conceptual illustration showing the adsorption of LY onto LA.
In vitro LY release from the NCT was studied at 1 wt% LA. According to previous reports, there
exists a good correlation among LA loading in thermogel, thermogel dissolution time and drug
release140. Therefore, an optimum concentration for LA (1 wt%) was chosen based on gelation
data in Figure 24. Since the incorporation of LA at a concentration of 1 wt% was necessary for a
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noticeable change in the gelation temperature of MBCP-2-composite, in vitro drug release study
was performed with the composite containing relatively low concentration (1 wt%) of LA rather
than the composite with 3 wt% of LA140.

Figure 29: Adsorption of LY on LA as a function of LY concentration. LY was measured using
BCA protein assay. The results represent the mean  SD for n=3.
In addition, the final formulation was a free-flowing liquid which could be injected through a 25gauge needle presenting clinical applicability. LY release (Figure 30) from MBCP-2 thermogels
was completed in 18 days, whereas only 45 % of the total drug was released in 18 days from
NCT with 1 wt% LA. LY adsorption onto LA significantly slowed LA release from the
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nanocomposite. On the other hand, free and unadsorbed LY released relatively fast from MBCP2 thermogel.

Figure 30: In vitro release of LY from MBCP-2 and NCT at pH 7.4. *Significant difference from
the cumulative percent LY release from NCT after 18 days (p < 0.05). The results represent the
mean  SD for n=3.
Previously, MBCP-2 thermogel sustained the release of FITC-dextran of molecular weight ≥ 40
kDa143. But the current NCT was able to sustain the release of an even smaller macromolecule.
However, it is essential that the therapeutics possess a surface charge, preferably positive charge,
for sustaining their release. With NCT approach, sustained delivery could be achieved for a
chemical irrespective of its molecular weight. Further, the system should not be limited to the
delivery of macromolecules, it should also find applications for small molecules drugs.
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Figure 31: CD spectra of native LY and LY in the release media. Molar ellipticity was plotted on
the vertical axis. All the solutions showed two negative bands at ~ 208 nm and ~220 nm. (a) LY
released from MBCP-2 thermogels; (b) LY released from NCT.
It is necessary that the model protein is structurally intact even after being released from the
NCT. Therefore, LY in the release media was investigated using CD spectroscopy to examine
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possible effects of formulation excipients, process conditions and release medium on secondary
structural arrangement of LY.

Figure 32: DSC thermographs of native LY and LY from the release media. (a) LY released from
MBCP-2 thermogels; (b) LY released from NCT. DSC was run in the temperature range of 0250 °C and all samples showed an endotherm in the temperature range 200-210 °C.
Figure 31 shows the CD spectra of native LA and LA from the release samples. LY consists of
segments with both α-helical and β-sheet arrangements. However, α-helical arrangement is
predominantly observed with a strong negative band in the range of 200-240 nm with two
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minima at 208 and 220 nm in the CD spectrum152. The spectra of native LY and the LY in
release medium are almost identical indicating that the formulation and in-vitro release processes
such as adsorption of LY and nanocomposite loading into thermogel were not detrimental to the
secondary structure of LY.
In addition to CD spectroscopy, DSC was run for released LY to determine the denaturation
temperature (Tm) of the protein in solid state145. Figure 32 shows the endotherms of native LY
and the LY in release media. LY required for DSC was collected by mixing and lyophilizing the
triplicate samples at particular time points. The onset temperature of the endotherm was
considered as Tm of the protein and LY showed a Tm of ~200 °C. Usually, an alteration in Tm of
LY represents a change in its conformation145. As observed in Figure 32, DSC thermographs of
LY in the release media were similar to native LY implying that the formulation conditions
didn‟t alter LY conformation.
Taken all together, a fine tuning of the compositions of the ingredients based on drug dose and
duration of delivery would result in a composite system that possesses clinically appropriate
characteristics. In addition, current NCT concept would be beneficial for an effective delivery of
therapeutic agents to diseases that necessitate sustained therapy.
4.5. Conclusions
A NCT with tunable gelation properties has been successfully developed. LA incorporation
significantly lowered gelation temperature of MBCP-2 solution. Also, the presence of LA
lowered CMT of MBCP-2 in water. Using DLS, concentration dependent interactions between
positively charged protein molecules and negatively charged LA were studied. Protein molecules
successfully separated the aggregates of LA in water. Due to increase in LA surface area at high
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LY concentration, adsorption of LY onto LA increased. LY adsorption onto LA significantly
slowed down its release from NCT. Further, formulation conditions didn‟t alter the secondary
structure of LY. Therefore, NCT could be suggested as a potential approach for sustained
delivery of LMW proteins.
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CHAPTER-5
MATRIX METALLOPROTEINASE-SENSITIVE THERMOGELLING POLYMER FOR
BIORESPONSIVE DRUG DELIVERY
5.1. Abstract
In this study, we proposed a new Pluronic® based thermogelling system containing MMP2
responsive peptide sequences. A novel thermosensitive multiblock copolymer comprising an
MMP2-labile octapeptide (Gly-Pro-Val-Gly-Leu-Ile-Gly-Lys) was synthesized from Pluronic®
triblock copolymer. The polymer was designed to form thermogel at body temperature and
degrade in presence of MMP overexpressed in the tumor. The synthesized polymer was a
multiblock copolymer with ~ 2.5 units of Pluronic®. The multiblock copolymer solutions
exhibited a reverse thermal gelation around body temperature. The gelation temperatures of the
multiblock copolymer solutions were lower than those of the corresponding Pluronic ® monomer
at a particular concentration. The cytotoxicity of the synthesized polymer was lower comparing
to its monomer. The solubility of hydrophobic anticancer drugs, PTX and CPT, were enhanced
in the polymer solutions via micelle formation. The synthesized polymer was preferentially
degraded in presence of MMP. PTX release was dependent on the enzyme concentration. These
findings suggest that the synthesized polymer has the potential as controlled drug delivery
system due to its unique phase transition and bioresponsive behavior.
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5.2. Introduction
The advance in technologies to engineer biomimetic materials has been an important
breakthrough that would greatly influence human health care6,75,76. Careful fabrication of
materials with precise consideration of the underlying cellular microenvironments made this
approach suitable for various biomedical applications. Biomimetic materials have been
consistently considered for drug delivery and tissue engineering77,78,80. These materials have
frequently been obtained by incorporating bioactive molecules such as proteins and peptides76,79.
Particularly, peptide conjugation has been proven as a vital approach to develop the biomimetic
materials to suit the biomedical needs12,43,81. Several approaches have been tried to engineer
these materials either to target the diseased tissue or to mimic the extracellular matrix10,11,42.
Targeted delivery of anticancer drugs has been one of the pressing research areas using bioactive
molecules. Anticancer therapeutic agents, such as methotrexate, PTX and cisplatin, have been
specifically delivered to tumor tissues by conjugating them to polymers using bioactive
molecules13,29,46,56,153. However, most polymeric prodrugs carrying pendent cytotoxic drugs have
been attached to polymer backbones via a peptide linker. The critical problems associated with
the polymeric prodrugs include low drug loading capacity and altered physicochemical
properties of the polymeric prodrug as a whole. Another drawback associated with the polymeric
prodrug is the release of peptide fragment-modified drug rather than intact drug molecules,
resulting in the reduced activity of parent drug82. An alternative to overcome the problems
associated with these approaches would be local drug delivery systems with enhanced drug
loading. Particularly, the local drug delivery systems based on amphiphilic thermosensitive
polymers has been investigated in recent years83-85. The thermosensitive polymer solution is a
free-flowing fluid at room temperature allowing easy administration into the body. The polymer
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solution turns into gel depot upon injecting into the body, where the gel depot acts a drug
reservoir90. In addition, the amphiphilic polymer can improve the solubility of insoluble drugs.
From a clinical perspective, the injectable thermogels have a great benefit because they allow
minimally invasive drug delivery directly to the diseased tissue.
Different thermogels were prepared with aqueous solutions of various polymeric materials such
as chitosan, hyaluronic acid, alginate, Pluronic® copolymers and poly(N-isopropylacrylamide)based copolymers86-88. Even though several different thermogelling systems have been prepared,
the drug release from the thermogels is mainly mediated by simple diffusion and non-specific
hydrogel erosion. These obstacles necessitate uncovering a specific mechanism to control drug
release from the thermogels. MMPs can act as in situ controlling tools to regulate drug release
from the thermogels. MMPs are zinc-dependent endopetidases that can cleave many of the
extracellular matrix proteins. Many of the MMPs are found to be overexpressed and active
during advanced stages of the cancer while they are minimally expressed in the normal tissue.
Particularly, MMP2 and 9 (Type IV collagenases) which degrade extracellular matrices have
been known to play a critical role in tumor progression, angiogenesis and metastasis81.
Therefore, the combination of thermogelling property and enzyme sensitivity would provide a
vital approach to engineer novel in-situ forming polymers that are suitable for bioresponsive
local drug delivery.
A peptide specifically degraded by MMPs is either incorporated into or conjugated to a
thermosensitive polymer to make a thermogel system which is sensitive to MMPs. A MMP13
sensitive peptide, QPQGLAK, has been incorporated into thermosensitive poly(N-isopropyl
acrylamide) hydrogel matrix10,11,96. The peptide in the hydrogel system provided a cross-linking
structure while maintaining thermosensitive properties. In addition, the system showed
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concentration dependent degradation towards MMP2. Recently, an enzymatically degradable
temperature sensitive polypeptide has been reported. The block copolymer, poly (ethylene
glycol)-block-poly (alanine-co-phenyl alanine) (PEG-PAF), showed temperature sensitivity in
water as well as degradability in the subcutaneous layer of rats43. Enzymes present in the
subcutaneous layer such as cathepsin B, cathepsin C and elastase were assumed to be responsible
for the degradation of polymer in vivo.
Here we report the synthesis of novel Pluronic®-based multiblock copolymer connected via a
MMP-2-sensitive peptide, Gly-Pro-Val-Gly-Leu-Ile-Gly-Lys-NH2 (GPVGLIGK-NH2). The
hypothesis behind this project is that the combination of thermosensitive Pluronic® and MMPsensitive peptide would result in a dual-stimuli-sensitive polymer which can form gel at body
temperature and allow bioresponsive degradation in presence of MMP. Physical properties and
in vitro cytotoxicity of the polymers were studied to assess in vivo applicability as a local drug
delivery system. Finally, two chemotherapeutic agents, PTX and CPT, have been released to
demonstrate the bioresponsive drug release from the thermogels.
5.3. Experimental
5.3.1. Materials
The peptide, GPVGLIGK-NH2, was synthesized by American Peptide Company (Vista, CA).
Pluronic® P85 and P104 were kindly provided from BASF Chemical Company (Florham Park,
NJ). Collagenase-IV was purchased from Sigma (Saint Louis, MO). PTX was obtained from LC
Laboratories (Woburn, MA). Polystyrene standards of molecular weights 1, 4, 20, 50 and 100K
were purchased from Polysciences, Inc. (Warrington, PA). All other chemicals were obtained
from Fisher Scientific (Pittsburgh, PA) and used without further purification.
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5.3.2. Polymer synthesis
5.3.2.1. Activation of triblock copolymer
Pluronic® P85 or P104 (10 g) was dried by azeotropic distillation from 150 mL of anhydrous
toluene. The dried Pluronic® was dissolved in 20 mL of anhydrous methylene chloride. About 2
mL of triethylamine (9.6 molar equiv.) was added to the reaction mixture at room temperature.
After cooling the reaction mixture in an ice bath, 4-nitrophenyl chloroformate (NPC) (8.0 molar
equiv.) was added. Initially, the mixture was allowed to react for 1 h at 0 oC. The reaction was
continued overnight at room temperature under magnetic stirring. After all the solvent was
removed, the activated Pluronic® (NPC-Pluronic®) was dissolved in 50 mL of anhydrous ethyl
acetate and filtered to remove precipitated triethylamine HCl. The NPC-Pluronic® was
recrystallized from 50 mL of diethyl ether to remove unreacted NPC. This step was repeated
twice to remove most of the unreacted NPC. Finally, the NPC-Pluronic® was dried under
reduced pressure and kept in a desiccator until peptide coupling.
5.3.2.2. Coupling of the peptide to activated triblock copolymer
The peptide (100 mg) and NPC-Pluronic® (1.1 molar amount to the peptide) were dissolved
separately in 1 mL of dimethyl acetamide (DMA). NPC- Pluronic® solution was added to the
peptide solution at room temperature by magnetic stirring. Triethylamine (5.0 molar amount to
the peptide) was slowly added to the reaction mixture. The reaction was carried out for one day
(at room temperature) or two days (first day at room temperature and second day at 50 oC) or
three days (one day at room temperature and two days at 50 oC). Dry nitrogen was flushed to
evaporate DMA from the reaction mixture. This crude multiblock copolymer was dissolved in
water and dialyzed (molecular weight cut off: 6000-8000, Spectra/Por®) against deionized water
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for two days with periodic media changes. The final product was freeze-dried to obtain polymer
powder. Two different multiblock copolymers, MMP-P85 from Pluronic® P85 and MMP-P104
from Pluronic® P104, were synthesized with the yields of 80% and 89%, respectively.
5.3.3. Polymer characterization
1

H-NMR was used to analyze the chemical structures of the synthesized polymers. Polymers

were dissolved in either CDCl3 or D2O and the spectra were recorded on a 400MHz NMR
spectrometer (Bruker UltrashieldTM 400 PLUS, Germany). Waters GPC system (Waters,
Milford, MA) equipped with a binary pump (Waters 1525), a refractive index detector (Waters
2414) and a Styragel HR4E column (300 × 7.8 mm I.D., 5 µm particle size) was used to obtain
the molecular weights and polydispersities of the polymers. THF was eluted at a flow rate of 1
mL/min at 25 oC. Polystyrene standards (1000-50000 Da) were also run to obtain a calibration
curve and the calibration curve was used to calculate the molecular weights of the polymers.
Thermograms of the polymers were obtained from DSC (Perkin Elmer Diamond DSC, Waltham,
MA). Melting temperatures of the polymers were determined from the thermograms thereafter.
DSC was run in the temperature range of 0 to 50 oC with a heating and cooling rate of 10 oC/min.
Initially, the samples were loaded in aluminum pans and equilibrated at 0 oC for 5 min. Dry
nitrogen flow at a rate of 20 mL/min was maintained throughout the analysis.
5.3.4. CMC of MMP-P104
The CMCs of Pluronic® P104 and MMP-P104 were determined by a dye solubilization method
using DPH89. Briefly, polymer solutions in the concentration range 1.0 × 10-5 to 10 wt% were
prepared. DPH solution (10 µL, 0.4 mM in methanol) was added to 1.0 mL of each polymer
solution. The polymer solutions were incubated at 25 oC for 24 h in a dark place. The absorbance
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values of the test solutions were recorded on a Lambda EZ201 UV spectrophotometer (Perkin
Elmer, Waltham, MA) at 377 and 391 nm. A graph was drawn plotting the difference between
two absorbance values on vertical axis and concentration on horizontal axis.
5.3.5. DSC of polymer solutions
DSC thermographs of Pluronic® P104 and MMP-P104 solutions were obtained in the
concentration range of 1 to 25 wt%. Sample solutions were prepared by dissolving specific
amount of polymer in deionized water with gentle stirring at 4 oC. Accurately weighed sample
solutions (6 mg) were placed in aluminum cells and reference cells were made up with same
amount of deionized water. DSC was run in the temperature range of -10 to 50 oC at a rate of
5oC/min. Samples were thermally equilibrated at -10 oC for 15 min before the scanning.
5.3.6. CD spectroscopy
The CD spectra of MMP-P104 and peptide solutions were analyzed in the wavelength range of
250 to 190 nm using a CD spectrometer (Olis® DSM 20 CD Spectrophotometer, Bogart, GA).
MMP-P104 and peptide solutions were prepared at 0.1 and 0.01 wt%, respectively. The sample
solutions were equilibrated at 4 oC overnight before the analysis. A cuvette (path length-1mm)
was charged with a sample solution and CD spectra were recorded at 15, 25, 35 and 45 oC. Molar
ellipticity of all the samples was calculated after a blank reference of water was subtracted from
the raw data.
5.3.7. In vitro cytotoxicity
In vitro cytotoxicity study was performed using MTT on HT1080 fibrosarcoma cells94. The cells
were cultured in Roswell Park Memorial Institute medium (RPMI). The RPMI was
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supplemented with 10% FBS and antibiotics. The cultured cells in 96-well plates (5 × 103
cells/well) were grown for 24 h at 37 oC. The culture medium was replaced with MMP-P104
solution (100 µL, 0.05-1.00 wt %) in serum-free DMEM. The cells were incubated for 4 h in
serum-free DMEM (100 µL) followed by 12 h incubation in 200 µL DMEM containing 10%
FBS. After 16 h of total incubation, the test solutions were replaced with fresh media (200 µL)
and 5 mg/mL MTT solution (20 µL). The cells were incubated for 4 h in MTT solution. Later,
the MTT solution was replaced with 400 µL dimethyl sulfoxide to dissolve internalized purple
formazan crystals. To measure the absorbance at 570 nm on a VICTOR3 VTM Multilabel
Counter (Perkin Elmer, MA, USA), 150 µL of the solution was transferred from each well into a
fresh 96-well plate. Cell viability was calculated as compared to phosphate buffered saline
(PBS)-treated cells (100 % survival).
5.3.8. Thermal gelation of polymeric solutions
5.3.8.1. Test tube inverting method
Polymer solutions were prepared by dissolving them in deionized water at 4 oC. A series of
polymer solutions at concentrations of 5, 10, 15, 20 and 25 wt% were prepared. Scintillation
vials (4mL) were loaded with 1mL of the polymer solution and incubated at 4 oC overnight. The
sol-gel and gel-sol phase transition temperatures of the each polymer solution were determined
with increments of 2 oC88,94. The experiment was conducted in the temperature range of 15 to 80
o

C. The temperature at which a polymer solution stopped flowing upon a tube inversion was

recorded as gelation temperature.
5.3.8.2. Falling ball method
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MMP-P104 solutions at concentrations of 10, 15, 20 and 25 wt% were prepared in deinonized
water. NMR tube of diameter 4.0 mm was filled with the polymer solution. The polymer solution
was incubated at 10 oC for 20 min. A steel ball (diameter (D) =1.97 mm, density (ρs) = 7.97
g/mL) was dropped through the polymer solution. The time (t) required for the steel ball to fall a
specified distance (d = 3 cm) was measured with a temperature increment of 2 oC per step for
each polymer concentration. The polymer solutions were equilibrated for 20 min at each
temperature. The intersection of extrapolated lines of travel time of the steel ball on a graph
plotted between temperature and the transit time gives the sol-gel transition temperature of the
polymer solution97. The dynamic viscosity (µ) was calculated using the following formula
µ = (γs - γf) D2/ (18v)
Where, the velocity of the falling ball (v) = d/t, specific gravity of the sphere (γs) = ρsg, specific
gravity of the polymer solution (γf) = ρfg, and acceleration due to gravity (g) = 980 cm/s2. The
density of the polymer solution (ρf) was assumed to be 1.0 g/cm3.
5.3.9. MMP-P104 degradation
The MMP-P104 solution was prepared at a concentration of 25 wt% in deinonized water. The
polymer solution (50 µL) was placed in 1mL vials and the vials were kept at 4 oC overnight. The
polymer solutions were incubated at 37 oC for 15 min for gelation. Phosphate buffer (0.1mL,
50mM) was added to first three vials (control). In another three vials, phosphate buffer
containing collagenase-IV (250µg/mL) was added. The degradation of the gels was stopped by
freezing the gels at predetermined time intervals. The frozen samples were then freeze-dried to
get the degraded polymer. GPC was run to check the molecular weight distribution of the
degraded polymer.
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Figure 33: Calibration curves for PTX and CPT developed using HPLC.
5.3.10. In vitro PTX release
MMP-P104 (250mg) was dissolved in 200µL of the acetone. After partial removal of acetone by
dry nitrogen flushing, 20µL of the acetone containing 500µg of PTX was added to the polymer
solution. By continuously mixing the polymer-drug mixture, the acetone was removed by dry
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nitrogen flushing. Finally, the polymer-drug mixture was vacuum dried in vacuum for 4 h to
remove the acetone completely. The MMP-P104-PTX mixture was dissolved in 750 µL water
with vigorous stirring at 4 oC. The polymer-drug solution (0.2 mL) was placed in each 2 mL vial
and allowed for gelation at 37 oC. The gels were equilibrated at this temperature for 15 min.
Phosphate buffer (1.6mL, 50mM) including 1% w/v Tween 80 was added to first set of vials
(control). Phosphate buffer (1.6mL, 50mM) composed of collagenase-IV (1, 10, 50 and
250µg/mL), Tween 80 (1% w/v), calcium chloride (0.5mM) and sodium azide (0.2mg/mL) was
added to another set of vials. While incubating at 37 oC, samples were collected and total
medium was replaced for every 12 h to maintain perfect sink conditions. The samples were
analyzed using HPLC. HPLC analysis conditions were described in Section 3.3.7. In addition,
the calibration curves for PTX and CPT were shown in Figure 33.
5.4. RESULTS & DISCUSSION
Multiblock copolymers (MMP-P85 and MMP-P104) were synthesized by conjugating
thermosensitive Pluronic® (P85 and P104), a group of triblock copolymer of PEG-PPG-PEG, to
a MMP-sensitive peptide (GPVGLIGK-NH2). The synthesis involves a two-step reaction as
described in Figure 34. Initially, the hydroxyl groups at the end of the Pluronic® were activated
by NPC to yield a nitrophenyl substituted Pluronic® (NPC- Pluronic®) at room temperature.
Then, the NPC-Pluronic® was purified by recrystallizing in diethyl ether 2-3 times. The
Pluronic® could also be activated by N-hydroxysuccinimidyl (NHS) ester. In such a case, the
ends of the Pluronic® should include carboxylic groups instead of hydroxyl groups. As this
method includes another step of modification, NPC is preferred over NHS for the activation of
Pluronic®. The 1H-NMR spectra of Pluronic® P104 and purified NPC-Pluronic® were shown in
Figure 35. The activation of Pluronic® was confirmed by the characteristic proton peaks of 4-
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nitrophenyl carbonate ranging from 7.4 to 8.4 ppm in 1H-NMR spectrum9. Figure 35A shows the
proton peak of hydroxyl protons (c) at each end of the Pluronic ®. The hydroxyl proton peak was
disappeared in the NMR spectrum (Figure 35B) upon the activation of Pluronic®. In addition, the
appearance of proton peak of the methylene group (f) at 4.45ppm confirmed the successful
activation of the Pluronic®.

Figure 34: Synthetic reaction scheme for the preparation of MMP-sensitive polymers from PEGPPG-PEG triblock copolymer (Pluronic®).
Several peptide sequences such as GPLGIAGQ, GPQGPAGQ, PVGLIG, and CGLDD have
shown MMP susceptibility42,46,82. An octapeptide sequence (GPVGLIGK-NH2) has been
synthesized to conjugate to the Pluronic® moiety. An MMP-sensitive hexapeptide (PVGLIG)82
was modified at the ends with two amino acids (glycine and lysine) to provide amine functional
groups on both ends.
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Figure 35: 1H-NMR spectra of (A) Pluronic® P104, (B) Activated Pluronic® P104 and (C)
MMP-P104. CDCl3 was used to measure the NMR spectra of all polymers.
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The modification in the peptide would allow the conjugation reaction to the terminals while
maintaining MMP-sensitive cleavage of the peptide at –GL–
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. The terminal amino groups of

the peptide allowed the linear oligomerization between the peptide and NPC- Pluronic®.
Table 5: Effect of different reaction conditions on the molecular weight of the final polymer. The
Mn values represent mean ± SD for n=3.

Polymer

Reaction conditions

Mn (g/mol)a

Mw/Mnb

1

RT (one day)

17570 (± 1060)

1.34

2

RT (one day) + 50 oC (one day)

21120 (± 960)

1.47

3

RT (one day) + 50 oC (two days)

23270 (± 1100)

1.33

a

Number average molecular weights determined by GPC

b

Polydispersities based on GPC measurements

The oligomerization was carried out for 24 h at room temperature. As Pluronic® of molecular
weight ~ 5000 may not be easily accessible for the oligomerizaion, the reaction time and
temperature were increased to check the effect of these parameters on the final molecular weight
of MMP-P104. Further, the final polymer was purified by dialysis using a regenerated cellulose
membrane (6000-8000 Da) to remove unreacted Pluronic® or peptide. Table 5 summarizes the
molecular weights of MMP-P104 at different reaction conditions. The molecular weight of
MMP-P104 slightly increased on increasing the reaction time and temperature. Figure 35C
shows the 1H-NMR spectrum of MMP-P104. The oligomerization was confirmed by the
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characteristic proton peaks of peptide and Pluronic® in the final polymer. The proton peaks at g
to v shows the presence of peptide and its conjugation to Pluronic®.
Table 6: Characterization of multiblock copolymers and triblock monomers. The Mn values
represent mean ± SD for n=3.

Polymer

Mn(g/mol)a

Mw/Mnb

Number of
repeating units

Tm (oC)c

Pluronic® P85

7410 (± 120) (4600d)

1.06

-

38.9

Pluronic® P104

8520 (± 110) (5900e)

1.05

-

39.4

MMP-P85

15290 (± 920)

1.47

2.06

28.5

MMP-P104

23540 (± 1100)

1.33

2.76

30.9

a

Number average molecular weights determined by GPC

b

Polydispersities based on GPC measurements

c

Melting temperatures determined by DSC

d,e

Molecular weights from BASF chemical company

Determined molecular characteristics of Pluronic® copolymers, MMP-P85 and MMP-P104 were
summarized in Table 6. The calculated molecular weights of MMP-P85 and MMP-P104 were
found to be 15290 and 23540 g/mol respectively. The molecular weight analysis indicates that
MMP-P85 and MMP-P104 are multiblock copolymers with 2.06 and 2.76 units of Pluronic® P85
and Pluronic® P104 respectively. Comparing to previously reported Pluronic®-based multiblock
copolymers88, multiblock copolymers with relatively low molecular weights were achieved
because of relatively high molecular weight peptide (~740 g/mol) which might limit the access
of the nitro group at the end of the Pluronic® to the amine group in the peptide during
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oligomerization. According to DSC data, the melting temperatures (Tm) of MMP-P85 and MMPP104 were found to be 28.5 and 30.9 oC. The Tm values of multiblock copolymers are lowered
comparing to the Tm values of Pluronic® monomers. This lowering of the Tm values of MMP-P85
and MMP-P104 may be due to the interrupted polymer packing by the incorporation of a peptide
in the polymer structure88.

Figure 36: CMC determination of MMP-P104 using a dye solubilization method. The CMC is
defined as the point of intersection of two exponential lines. The CMC of MMP-P104 was found
to be 0.208 (±0.012) wt%. The CMC value represents the mean ±SD of three experiments.
The relatively high molecular weight and acceptable gelation properties of MMP-P104 made this
multiblock copolymer an interested candidate comparing to MMP-P85. So, the further
characterization was mainly performed with MMP-P104. A hydrophobic dye solubilization
method was used to measure the CMC of MMP-P10488,89. DPH is a hydrophobic molecule
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which has strong absorbance at 344, 358 and 377nm. The absorbance of DPH greatly depends on
the hydrophobicity of the local environment. DPH has low absorbance (377 nm) in an aqueous
environment while it has high absorbance in hydrophobic environment. When DPH probe is
mixed with micelle solution, it is trapped in the hydrophobic core of the micelle, and its
absorbance will address the hydrophobic nature of the core. The absorbance of DPH has sharply
increased at CMC of the MMP-P104 (Figure 36). The CMC was calculated by extrapolating the
absorbance versus logarithmic concentration. The CMC of MMP-P104 was found to be 0.208
(±0.012) wt% which is slightly lower than the CMC of Pluronic® P104 (0.300 (±0.009) wt%).

Figure 37: Determination of CMT of MMP-P104 solutions by DSC. The onset temperature of
the endothermic peak represents the CMT of the solution.
This lowering of the CMC is mainly attributed to the increased molecular weight of MMP-P104.
This can be explained in two ways. First, at a given PPO/PEO ratio, higher molecular weight
Pluronic® polymers form micelles more readily than the lower molecular weight polymers98.
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Second, the easy micelle formation is favored for multiblock copolymer as covalently bonded
PPGs facilitate easy hydrophobic core formation during micelle structuring89.
The polymer solutions were further characterized for CMT. The micellization process is
characterized by endothermic peak during the heating cycle in DSC. Figure 37 shows the
endotherms of all measured concentrations in the heating range 0 to 40 oC. The onset
temperature at which micelles start to form is considered as the CMT at the particular polymer
concentration. The CMT of Pluronic® P104 solutions were found to be 23.35, 19.87, 16.96,
14.54, 11.13 and 7.55 oC for 1, 5, 10, 15, 20 and 25 wt% respectively. The CMTs of MMP-P104
were 22.65, 19.51, 16.77, 14.25, 10.93 and 5.78 oC for 1, 5, 10, 15, 20 and 25 wt% respectively.
The trend in CMT changes with polymer concentration was in accordance with phase transition
of Pluronic® P10498,100. The CMT of MMP-P104 slightly lowered than that of Pluronic® P104 at
each polymer concentration. This is mainly due to the higher molecular weight of the multiblock
copolymer comparing to Pluronic® P104. High molecular weight block polymers are known to
be more favorable for micelle formation than low molecular weight polymers98.
Secondary structures of MMP-P104 and peptide in solution were analyzed using CD
spectroscopy as a function of temperature. Formation of α- helices (one positive band centered at
~ 195 nm and two negative bands between 205-225 nm) or β- sheets (one positive band centered
at ~ 195 nm and one negative band between 210-220 nm) or random coils (one negative band
centered at ~ 195 nm and one positive band centered at ~ 215 nm) will show characteristic CD
spectra81. Spectra of both peptide and MMP-P104 suggested the random coil arrangement of
MMP-sensitive peptide in the multiblock copolymer in an aqueous environment. Pluronic® did
not show a considerable effect on the random coil arrangement of peptide in water. Figure 38
shows the CD spectra of MMP-P104 at 15, 25, 35 and 45 oC.
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Figure 38: CD spectra of MMP-P104 at different temperatures. Molar ellipticity was plotted on
the vertical axis. All the solutions showed a negative band at ~ 195 nm and a positive band at
~215 nm.
As the temperature increased, a considerable decrease in the negative band at 195 nm was
observed. In addition, a small decrease in the positive band at 215 nm was also observed. This
pattern indicates a slight change in the secondary structural arrangement of MMP-P104,
suggesting the possibility of more ordered structures between peptides comparing to random
coils with a temperature increment.
Cytotoxicity of Pluronic® P104 and MMP-P104 was assessed by MTT assay using HT1080
fibrosarcoma cells. As HT1080 cells are known to express different types of MMPs, especially
MMP 2 and 9, they were chosen for the assessment of the cytotoxicity101,102.
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Figure 39 shows the results of MTT assay in the polymer concentration ranging from 0.05 to
1.00 wt%. It is shown that MMP-P104 resulted in a greater cell viability comparing to
monomeric Pluronic® P104.

Figure 39: Cell viability as a function of concentration was measured for Pluronic® P104 and
MMP-P104 on HT1080 cells. The results represent the mean ±SD for n=3.
The difference in cytotoxicity can be attributed to molecular weight difference between MMPP104 and Pluronic® P104. Previously, MBCP-2 of molecular weight ~ 40000 showed cell
viability of >80%88. Therefore the increase in polymer molecular weight would be a vital means
to improve the biocompatibility of MMP-P104. Biocompatible MMP-104 with increased
molecular weight would provide an ideal cancer drug delivery platform which can achieve
bioresponsive drug release as well as enhanced cytotoxicity to cancer cells with the sensitizing
effect from released Pluronic® P104.
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The fundamental properties such as sol-gel and gel-sol transition temperatures of Pluronic® P104
and MMP-P104 polymer solutions were evaluated by test tube inverting method and falling ball
method. Figure 40 shows the phase diagram of MMP-P104 and Pluronic® P104 at different
polymer concentrations.

Figure 40: Phase diagrams of Pluronic® P104 and MMP-P104 aqueous solutions constructed
by both test tube inverting method and falling ball methods. The results represent mean ±SD for
n=3.
The sol-gel transition temperatures determined by test tube inverting method are in good
agreement with the values determined by falling ball method. Due to an extended equilibration
time during the execution of falling ball method, a slight difference in gelation temperature was
observed between two methods. At all polymer concentrations tested for gelation, MMP-P104
solutions were free flowing liquids at room temperature which could be easily injected through
25-guage needle. Upon increasing the temperature to 37 oC, the solution immediately turned into
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gel depending on the polymer concentration. Figure 41 shows the change in viscosities with
temperature of MMP-P104 solutions at different polymer concentrations.

Figure 41: Dynamic viscosity measurement of MMP-P104 solutions as a function of
temperature. Dynamic viscosity was measured using falling ball method for different polymer
concentrations.
The viscosities are below 500 g/cm.sec-1 during the “sol” state where as they ranged between
1000-9000 g/cm.sec-1 during the “gel” phase for all the measured concentrations. MMP-P104
solutions showed sol-gel-sol transition in the range of 10-25 wt%. But, the Pluronic® P104 (25
wt%) solution showed sol-gel-sol-gel-sol transition on increasing the temperature. Formation of
isotropic or cubic crystalline phases is responsible for gelation at low temperature whereas
formation of multi-phases (cubic/hexagonal/lamellar) cause gelation at high temperature104. The
sol-gel transition temperatures of MMP-P104 were lowered comparing to Pluronic® P104 at
particular concentration.
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Figure 42: GPC chromatographs showing MMP-P104 polymer degradation in presence or
absence of MMP. The multiblock copolymers were degraded into lower molecular weight
monomers. At 0 h, a small amount of unreacted Pluronic® P104 was detected in the
chromatographs of MMP-P104.
For example, at 25 wt% the gelation temperature of Pluronic® P104 was 68.5 oC whereas the
gelation temperature of MMP-P104 was 30.7 oC. In addition to the sol-gel transition, the CGC of
MMP-P104 was also lowered comparing to the CGC of Pluronic® P104. This lowering of CGC
and sol-gel transition temperatures was mainly attributed to the extended and enforced chain
entanglements due to increased molecular weight in MMP-P104 comparing to Pluronic® P104.
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Figure 42 shows the GPC chromatographs of degraded MMP-P104 in presence or absence of
MMP. An MMP concentration of 250 µg/mL was chosen to study the polymer degradation in a
facilitated condition. MMP-P104 degraded rapidly in presence of MMP showing complete
polymer degradation within 24 h while the polymer degraded much slower in the absence of
MMP. Complete polymer degradation was observed at the end of day 12 without the enzyme.
GPC was also run on Pluronic® P104 to compare the changes in chromatographs. The
chromatograph of completely degraded MMP-P104 was similar to that of Pluronic® P104
indicating that the multiblock copolymer degraded into its monomeric units. Considering the
MMP-cleavable site in the peptide, the possible degradation products of multiblock copolymer
would be the Pluronic® monomers with four amino acids on both the terminals. However,
remaining peptide segments will be eventually degraded into amino acids by proteases in the
body.
MMP-P104 solutions demonstrated quick gelation which occurred within a minute below body
temperature at a polymer concentration of 25 wt%. Based on this observation, 25 wt% was
selected for in vitro PTX release. The achieved PTX concentration in 25 wt% MMP-P104
solution was found to be 0.850 mg/mL. The achieved PTX concentration was a 200-fold increase
in PTX solubility in water with a PTX concentration change from 0.004 mg/mL to 0.850 mg/mL
in the presence of the polymer. PTX and CPT release from the MMP-sensitive thermogel was
investigated at different MMP concentrations as well as in MMP free media. Release profiles
have been summarized in Figure 43 and 44. PTX release lasted for 2, 5 and 8 days at MMP
concentrations of 50, 10, and 1 µg/mL, respectively. In addition, CPT released quickly in 1 day
at 250 µg/mL of MMP. Rapid drug release due to the erosion of the gels was observed in
presence of MMP. Based on the consistency between PTX release and polymer degradation, it is

107

notable that erosion played a main role in the drug release in presence of MMP. On the other
hand, both erosion and diffusion have caused sustained drug release up to 13 days in the absence
of MMP.

Figure 43: PTX release at different MMP concentrations such as 0, 1, 10 and 50 µg/mL. The
results represent mean ±SD for n=3.

Figure 44: CPT release at 0 and 250 µg/mL of MMP. The results represent mean ±SD for n=3.
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Figure 45: PTX release from MMP-P104 thermogels with an alterating challenge of MMP free
medium following MMP containing medium. The addition of MMP in the release medium at a
concentration of 250 µg/mL triggered a fast drug release. The results represent mean ±SD for
n=3.
Precise drug release from an in-situ formed hydrogel depot to achieve a local therapeutic drug
concentration is a difficult task since there is no viable mechanism to control drug release once it
forms a depot. The hydrogel depot is expected to monotonously release incorporated drug at a
predetermined rate until incorporated drug is completely exhausted. The presence of an extra
mechanism that is able to control drug release even beyond in-situ depot formation and secure a
therapeutic level of drug will be highly desirable for successful local drug delivery particularly
for detrimental diseases such as cancers. MMP-sensitive thermogels were tested for cooperative
drug release by diffusion and enzymatic hydrogel degradation which may be useful for the
achievement of effective local drug delivery potentially for cancers. The thermogel was
challenged with an alternating medium change to simulate an MMP-elevation in cancer. As
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shown in Figure 45, the thermogel immediately increased PTX release upon a medium
replacement from MMP-free medium to MMP-containing medium. Upon an addition of MMP at
a concentration of 250 µg/mL, cumulative PTX release was dramatically increased from 27% to
complete drug release within 24 hr. The MMP-sensitive drug release demonstrated in Figures 43,
44 and 45 is completely in accordance with the polymer degradation presented in Figure 42.
Marked increase in drug release from the MMP-sensitive thermogel suggests the capability of
MMP-sensitive thermogel as a bioresponsive local drug delivery platform which would be
particularly applicable for cancer drug delivery.
5.5. Conclusions
MMP-sensitive thermogelling polymers have been successfully synthesized for potential drug
delivery applications by incorporating an MMP-sensitive peptide into an amphiphilic multiblock
copolymer. The aqueous solution of the synthesized polymer underwent gelation at body
temperature. In addition, the gelation temperature of the polymer solutions varied depending on
the polymer concentration. The cytotoxicity of the synthesized polymer was lower comparing to
the corresponding monomer. The polymer was rapidly degraded in presence of MMP. The
synthesized polymer greatly enhanced the solubility of hydrophobic cancer drugs, PTX and CPT.
The polymer gels exhibited the release of incorporated drug in a bioresponsive manner.
“Reprinted from Acta Biomaterialia, 7, Garripelli VK, Kim JK, Son S, Kim WJ, Repka MA, Jo
S, Matrix metalloproteinase-sensitive thermogelling polymer for bioresponsive local drug
delivery, 1984-1992, Copyright (2011), with permission from Elsevier Limited.”
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CHAPTER-6
CONCLUSIONS
Thermosensitive hydrogels have already been successfully employed in various
biomedical applications. The unique properties of these systems greatly influence the future of
biomaterials, especially in the fields of controlled drug delivery and tissue engineering. In the
current research work, two bioresponsive thermogelling systems based on multiblock
copolymers were succesfully developed. The multiblock copolymers were synthesized from
amphiphilic triblock copolymers, Pluronic® P85 and P104. The thermogelling polymers were
synthesized for local drug delivery applications by incorporating responsive moieties (pHresponsive and MMP-responsive) into the multiblock copolymers. The structural and
physicochemical characterization of the synthesized polymers was successfully completed by
different techniques such as NMR, GPC, CD, DSC, etc. The aqueous solutions of the polymers
showed concentration dependent gelation. Most importantly, the polymer solutions underwent
gelation at body temperature (37 °C). The synthesized polymers showed either minimum or no
cytotoxicity indicating that the thermogelling systems are biocompatibile. In addition to the two
thermosensitive polymers, a NCT has been developed and characterized for sustained delivery of
small proteins. Finally, the ability of the thermogels to manipulate the drug release shows that
the current thermogel and NCT systems hold great potential for controlled drug delivery.
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